# US 2022/0064226 A1 · Panel comprising Borrelia MHC multimers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064226 A1
- Document ID: US20220064226A1
- Status: Published application
- Kind: A1
- Application number: 17/415,077
- Filed: 2019-12-17
- Published: 2022-03-03
- Earliest claimed: 2018-12-17
- Assignees: Immudex ApS
- Applicants: Immudex ApS
- Inventors: Liselotte BRIX; Kivin JACOBSEN; Amir AMERI
- Web page: https://patentgrep.com/patent/US20220064226A1

## CPC

- C07K 14/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- A61K 49/14: Peptides, e.g. proteins
- A61P 31/04: Antibacterial agents
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- G01N 15/1434: Optical arrangements
- G01N 33/56911: {Bacteria}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/605: {MHC molecules or ligands thereof}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- G01N 15/01: specially adapted for biological cells, e.g. blood cells (investigating sedimentation of particle suspensions in blood G01N15/05)
- G01N 2015/1006: {for cytology}
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.

## Claims

### Claim 1

A panel comprising one or more MHC multimers comprising (a-b-P)n,
wherein n>1,
wherein polypeptides a and b together form a functional MHC protein capable of binding peptide P, and (a-b-P) is a MHC-peptide complex formed when peptide P binds to the functional MHC protein,
wherein each MHC-peptide complex of a MHC multimer is associated with one or more multimerization domains;
wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 2 (depends on 1)

The panel according to claim 1 comprising one MHC multimer, wherein said MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 3 (depends on 1)

The panel according to claim 1 comprising two or more MHC multimers, wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 4

The panel according to any of the preceding claims comprising one or more MHC multimers, for example 2 or more MHC multimers, such as 3 or more MHC multimers, for example 4 or more MHC multimers, such as 5 or more MHC multimers, for example 6 or more MHC multimers, such as 7 or more MHC multimers, for example 8 or more MHC multimers such as 9 or more MHC multimers, for example 10 or more MHC multimers, for example 11 or more MHC multimers, such as 12 or more MHC multimers, for example 13 or more MHC multimers, such as 14 or more MHC multimers, for example 15 or more MHC multimers, such as 16 or more MHC multimers, for example 17 or more MHC multimers such as 18 or more MHC multimers, for example 19 or more MHC multimers, for example 20 or more MHC multimers,
wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 5

The panel according to any of the preceding claims comprising 1 MHC multimer, for example 2 MHC multimers, such as 3 MHC multimers, for example 4 MHC multimers, such as 5 MHC multimers, for example 6 MHC multimers, such as 7 MHC multimers, for example 8 MHC multimers such as 9 MHC multimers, for example 10 MHC multimers, for example 11 MHC multimers, such as 12 MHC multimers, for example 13 MHC multimers, such as 14 MHC multimers, for example 15 MHC multimers, such as 16 MHC multimers, for example 17 MHC multimers such as 18 MHC multimers, for example 19 MHC multimers, for example 20 MHC multimers, wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 6

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42;
i) wherein one or more of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide OppA; and/or
ii) wherein one or more of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA; and/or
iii) wherein one or more of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF; and/or
iv) wherein one or more of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB; and/or
v) wherein one or more of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42.

### Claim 7

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of
i) OppA (SEQ ID NOs:1-9),
ii) DbpA (SEQ ID NOs:10-20),
iii) FlhF (SEQ ID NOs:21-28),
iv) FlaB (SEQ ID NOs:29-37), and/or
v) P37-42 (SEQ ID NOs:38-39).

### Claim 8

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises
i) an antigenic peptide P derived from Borrelia antigenic polypeptide OppA, such as OppA (SEQ ID NOs:1-9);
ii) an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA, such as DbpA (SEQ ID NOs:10-20);
iii) an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF, such as FlhF (SEQ ID NOs:21-28);
iv) an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB, such as FlaB (SEQ ID NOs:29-37); and/or
v) an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42, such as P37-42 (SEQ ID NOs:38-39).

### Claim 9

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide OppA, such as OppA (SEQ ID NOs:1-9).

### Claim 10

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA, such as DbpA (SEQ ID NOs:10-20).

### Claim 11

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF, such as FlhF (SEQ ID NOs:21-28).

### Claim 12

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB, such as FlaB (SEQ ID NOs:29-37).

### Claim 13

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42, such as P37-42 (SEQ ID NOs:38-39).

### Claim 14

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA and DbpA,
OppA and FlhF,
OppA and FlaB,
OppA and P37-42,
DbpA and FlhF,
DbpA and FlaB,
DbpA and P37-42,
FlhF and FlaB,
FlhF and P37-42, or
FlaB and P37-42.

### Claim 15

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA (SEQ ID NOs:1-9) and DbpA (SEQ ID NOs:10-20),
OppA (SEQ ID NOs:1-9) and FlhF (SEQ ID NOs:21-28),
OppA (SEQ ID NOs:1-9) and FlaB (SEQ ID NOs:29-37),
OppA (SEQ ID NOs:1-9) and P37-42 (SEQ ID NOS:38-39),
DbpA (SEQ ID NOs:10-20) and FlhF (SEQ ID NOs:21-28),
DbpA (SEQ ID NOs:10-20) and FlaB (SEQ ID NOs:29-37),
DbpA (SEQ ID NOs:10-20) and P37-42 (SEQ ID NOS:38-39),
FlhF (SEQ ID NOs:21-28) and FlaB (SEQ ID NOs:29-37),
FlhF (SEQ ID NOs:21-28) and P37-42 (SEQ ID NOS:38-39), or
FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39).

### Claim 16

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA, DbpA and FlhF,
OppA, DbpA and FlaB,
OppA, DbpA and P37-42,
OppA, FlhF and FlaB,
OppA, FlhF and P37-42,
OppA, FlaB and P37-42,
DbpA, FlhF and FlaB,
DbpA, FlhF and P37-42, or
FlhF, FlaB and P37-42.

### Claim 17

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20) and FlhF (SEQ ID NOs:21-28),
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20) and FlaB (SEQ ID NOs:29-37),
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20) and P37-42 (SEQ ID NOS:38-39),
OppA (SEQ ID NOs:1-9), FlhF (SEQ ID NOs:21-28) and FlaB (SEQ ID NOs:29-37),
OppA (SEQ ID NOs:1-9), FlhF (SEQ ID NOs:21-28) and P37-42 (SEQ ID NOS:38-39),
OppA (SEQ ID NOs:1-9), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39),
DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28) and FlaB (SEQ ID NOs:29-37),
DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28) and P37-42 (SEQ ID NOS:38-39), or
FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39).

### Claim 18

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA, DbpA, FlhF and FlaB,
OppA, DbpA, FlhF, P37-42,
OppA, FlhF, FlaB and P37-42,
OppA, DbpA, FlaB and P37-42,
OppA, DbpA, FlhF and P37-42, or
DbpA, FlhF, FlaB and P37-42.

### Claim 19

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide:
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28) and FlaB (SEQ ID NOs:29-37),
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), P37-42 (SEQ ID NOS:38-39),
OppA (SEQ ID NOs:1-9), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39),
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39),
OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28) and P37-42 (SEQ ID NOS:38-39), and/or
DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39).

### Claim 20

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 21

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOS:38-39).

### Claim 22

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P selected from the group consisting of:
i) antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20),
ii) antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19),
iii) antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20),
iv) antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and/or
v) antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20).

### Claim 23

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P selected from the group consisting of:
i) antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A-1, Table A-2, Table A-3, Table A-4, Table A-5, Table A-6, Table A-7, Table A-8, Table A-9, Table A-10, Table A-11, Table A-12, Table A-13, Table A-14, Table A-15, table A-16, Table A-17, Table A-18, Table A-19, or Table A-20,
ii) antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B-1, Table B-2, Table B-3, Table B-4, Table B-5, Table B-6, Table B-7, Table B-8, Table B-9, Table B-10, Table B-11, Table B-12, Table B-13, Table B-14, Table B-15, table B-16, Table B-17, Table B-18, or Table B-19,
iii) antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C-1, Table C-2, Table C-3, Table C-4, Table C-5, Table C-6, Table C-7, Table C-8, Table C-9, Table C-10, Table C-11, Table C-12, Table C-13, Table C-14, Table C-15, table C-16, Table C-17, Table C-18, Table C-19, or Table C-20,
iv) antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D-1, Table D-2, Table D-3, Table D-4, Table D-5, Table D-6, Table D-7, Table D-8, Table D-9, Table D-10, Table D-11, Table D-12, Table D-13, Table D-14, Table D-15, table D-16, Table D-17, Table D-18, Table D-19, or Table D-20, and/or
v) antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E-1, Table E-2, Table E-3, Table E-4, Table E-5, Table E-6, Table E-7, Table E-8, Table E-9, Table E-10, Table E-11, Table E-12, Table E-13, Table E-14, Table E-15, table E-16, Table E-17, Table E-18, Table E-19, or Table E-20.

### Claim 24

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P selected from the group consisting of: YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEFI (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127), SQGGVNSPV (SEQ ID NO: 5112), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 25

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P selected from the group consisting of:
i) YLNTKSNGNYEI (SEQ ID NO: 359) and FLSIFTQGYT (SEQ ID NO: 241) derived from OppA,
ii) GIYDLILNA (SEQ ID NO: 2761) derived from DbpA,
iii) YIKDINEFI (SEQ ID NO: 4479) derived from FlhF,
iv) IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112) derived from FlaB, and/or
v) IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531) derived from P37-42.

### Claim 26

The panel according to any of the preceding claims, wherein each of said one or more MHC multimers comprises an antigenic peptide P selected from the group consisting of:
i) YLNTKSNGNYEI (SEQ ID NO: 359) derived from OppA, FLSIFTQGYT (SEQ ID NO: 241) derived from OppA, GIYDLILNA (SEQ ID NO: 2761) derived from DbpA, and YIKDINEFI (SEQ ID NO: 4479) derived from FlhF,
ii) IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112) derived from FlaB, and/or
iii) IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531) derived from P37-42.

### Claim 27

The panel according to any of the preceding claims, said panel comprising or consisting of 11 MHC multimers, wherein each of said 11 MHC multimers comprise an antigenic peptide P selected from the group consisting of: YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEFI (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127), SQGGVNSPV (SEQ ID NO: 5112), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 28

The panel according to any of the preceding claims, said panel comprising or consisting of an MHC multimer comprising YLNTKSNGNYEI (SEQ ID NO: 359), an MHC multimer comprising FLSIFTQGYT (SEQ ID NO: 241), an MHC multimer comprising GIYDLILNA (SEQ ID NO: 2761), an MHC multimer comprising YIKDINEFI (SEQ ID NO: 4479), an MHC multimer comprising IQIEIEQLTDEI (SEQ ID NO: 5126), an MHC multimer comprising RMISDQRANLGA (SEQ ID NO: 5127), an MHC multimer comprising SQGGVNSPV (SEQ ID NO: 5112), an MHC multimer comprising MLDEAKDKL (SEQ ID NO: 5516), an MHC multimer comprising FMEQATNSWI (SEQ ID NO: 5530), an MHC multimer comprising NLVFSSLFL (SEQ ID NO: 5510) and an MHC multimer comprising KLAESIYKRL (SEQ ID NO: 5531).

### Claim 29

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9), such as derived from Borrelia antigenic polypeptide OppA of species Afzelii (SEQ ID NOs:1-3), or derived from Borrelia antigenic polypeptide OppA of species Garinii (SEQ ID NOs:4-6), or derived from Borrelia antigenic polypeptide OppA of species Burgdorferi (SEQ ID NOs:7-9).

### Claim 30

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide OppA selected from the group consisting of (SEQ ID NO:1), (SEQ ID NO:2), (SEQ ID NO:3), (SEQ ID NO:4), (SEQ ID NO:5), (SEQ ID NO:6), (SEQ ID NO:7), (SEQ ID NO:8) and (SEQ ID NO:9).

### Claim 31

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20), such as derived from Borrelia antigenic polypeptide OppA of species Afzelii (SEQ ID NOs:10-13), or derived from Borrelia antigenic polypeptide DbpA of species Garinii (SEQ ID NOs:14-17), or derived from Borrelia antigenic polypeptide DbpA of species Burgdorferi (SEQ ID NOs:18-20).

### Claim 32

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide DbpA selected from the group consisting of (SEQ ID NO:10), (SEQ ID NO:11), (SEQ ID NO:12), (SEQ ID NO:13), (SEQ ID NO:14), (SEQ ID NO:15), (SEQ ID NO:16), (SEQ ID NO:17), (SEQ ID NO:18), (SEQ ID NO:19), and (SEQ ID NO:20).

### Claim 33

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28), such as derived from Borrelia antigenic polypeptide FlhF of species Afzelii (SEQ ID NOs:21-22), or derived from Borrelia antigenic polypeptide FlhF of species Garinii (SEQ ID NOs:23-25), or derived from Borrelia antigenic polypeptide FlhF of species Burgdorferi (SEQ ID NOs:26-28).

### Claim 34

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide FlhF selected from the group consisting of (SEQ ID NO:21), (SEQ ID NO:22), (SEQ ID NO:23), (SEQ ID NO:24), (SEQ ID NO:25), (SEQ ID NO:26), (SEQ ID NO:27), and (SEQ ID NO:28).

### Claim 35

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37), such as derived from Borrelia antigenic polypeptide FlaB of species Afzelii (SEQ ID NOs:29-32), or derived from Borrelia antigenic polypeptide FlaB of species Garinii (SEQ ID NOs:33-35), or derived from Borrelia antigenic polypeptide FlaB of species Burgdorferi (SEQ ID NOs:36-37).

### Claim 36

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide FlaB selected from the group consisting of (SEQ ID NO:29), (SEQ ID NO:30), (SEQ ID NO:31), (SEQ ID NO:32), (SEQ ID NO:33), (SEQ ID NO:34), (SEQ ID NO:35), (SEQ ID NO:36), and (SEQ ID NO:37).

### Claim 37

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOs:38-39), such as derived from Borrelia antigenic polypeptide P37-42 of species Garinii (SEQ ID NO:38), or derived from Borrelia antigenic polypeptide FlaB of species Burgdorferi (SEQ ID NOs:39).

### Claim 38

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from Borrelia antigenic polypeptide P37-42 selected from the group consisting of (SEQ ID NO:38) and (SEQ ID NO:39).

### Claim 39

The panel according to any of the preceding claims, wherein said one or more antigenic peptides P are derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42 each derived from a Borrelia species or subspecies selected from the group consisting of: Borrelia anserina, Borrelia barbouri, Borrelia afzelii, Borrelia afzelii ACA-1, Borrelia afzelii K78, Borrelia afzelii PKo, Borrelia andersonii, Borrelia bissettii, Borrelia burgdorferi, Borrelia burgdorferi 118a, Borrelia burgdorferi 156a, Borrelia burgdorferi 29805, Borrelia burgdorferi 64b, Borrelia burgdorferi 72a, Borrelia burgdorferi 80a, Borrelia burgdorferi 94a, Borrelia burgdorferi B31, Borrelia burgdorferi Bol26, Borrelia burgdorferi CA-11.2a, Borrelia burgdorferi W191-23, Borrelia burgdorferi ZS7, Borrelia californiensis, Borrelia garini, Borrelia garini PBi, Borrelia garini PBr, Borrelia genomosp. 1, Borrelia genomosp. 2, Borrelia japonica, Borrelia lusitaniae, Borrelia spielmanii, Borrelia spielmanii A14S, Borrelia tanukii, Borrelia turdi, Borrelia valaisiana, Borrelia valaisiana VS116, Candidatus Borrelia texasensis, Borrelia sp. AA4Pool, Borrelia sp. A1-1, Borrelia sp. B31, Borrelia sp. BC-1, Borrelia sp. CA1133, Borrelia sp. CA1176, Borrelia sp. CA128, Borrelia sp. CA13, Borrelia sp. CA134, Borrelia sp. CA142, Borrelia sp. CA20, Borrelia sp. CA22, Borrelia sp. CA27, Borrelia sp. CA28, Borrelia sp. CA29, Borrelia sp. CA31, Borrelia sp. CA33, Borrelia sp. CA370, Borrelia sp. CA372, Borrelia sp. CA378, Borrelia sp. CA388, Borrelia sp. CA393, Borrelia sp. CA394, Borrelia sp. CA395, Borrelia sp. CA399, Borrelia sp. CA400, Borrelia sp. CA401, Borrelia sp. CA402, Borrelia sp. CA404, Borrelia sp. CA411, Borrelia sp. CA426, Borrelia sp. CA443, Borrelia sp. CA446, Borrelia sp. CA448, Borrelia sp. CA462, Borrelia sp. CA468, Borrelia sp. CA502, Borrelia sp. CA504, Borrelia sp. CA507, Borrelia sp. CA547, Borrelia sp. CA552, Borrelia sp. CA8, Borrelia sp. D22, Borrelia sp. D35, Borrelia sp. FD-1, Borrelia sp. FL18, Borrelia sp. FL27, Borrelia sp. FL35, Borrelia sp. FL42, Borrelia sp. HN6, Borrelia sp. HN7, Borrelia sp. HN8, Borrelia sp. HNM13, Borrelia sp. HNM14, Borrelia sp. HNM19, Borrelia sp. IA1, Borrelia sp. Ir-3519, Borrelia sp. Ir-4721, Borrelia sp. Ir-4812, Borrelia sp. Ir-5215, Borrelia sp. LV5, Borrelia sp. MI-2, Borrelia sp. MI-5, Borrelia sp. MI-6, Borrelia sp. MI-8, Borrelia sp. MI-9, Borrelia sp. MOD-1, Borrelia sp. MOD-5, Borrelia sp. MOK-3a, Borrelia sp. MOS-1b, Borrelia sp. NE49, Borrelia sp. NE581, Borrelia sp. PHaP, Borrelia sp. PSigll, Borrelia sp. SCGT-10, Borrelia sp. SCGT-8a, Borrelia sp. SCI-2, Borrelia sp. SCW-30h, Borrelia sp. SI-1, Borrelia sp. SI-10, Borrelia sp. SM-1, Borrelia sp. SV1, Borrelia sp. W97F51, Borrelia sp. Z41293, Borrelia sp. Z41493, Borrelia coriaceae, Borrelia crocidurae, Borrelia duttonii, Borrelia duttonii Ly, Borrelia hermsii, Borrelia hermsii DAH, Borrelia hispanica, Borrelia lonestari, Borrelia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia recurrentis, Borrelia recurrentis Ai, Borrelia sinica, Borrelia theileri, Borrelia turcica, Borrelia turicatae, Borrelia turicatae 91E135, Borrelia sp., Borrelia sp. ‘Lake Gaillard’, Borrelia sp. 000133, Borrelia sp. 010298, Borrelia sp. 10MT, Borrelia sp. 5145, Borrelia sp. 57Nsk, Borrelia sp. 5MT, Borrelia sp. 6T04-2, Borrelia sp. BR, Borrelia sp. BR 2007, Borrelia sp. C5-N52, Borrelia sp. CB-A1, Borrelia sp. CB-A11, Borrelia sp. CB-A3, Borrelia sp. EFL-SO100110, Borrelia sp. IK/23, Borrelia sp. IM/16, Borrelia sp. IM/19, Borrelia sp. KR1, Borrelia sp. KR3, Borrelia sp. LB-2001, Borrelia sp. LB-M56, Borrelia sp. LB-W100, Borrelia sp. MK-N61, Borrelia sp. NR-N8, Borrelia sp. OkME1, Borrelia sp. PAnz, Borrelia sp. PJes, Borrelia sp. PMai, Borrelia sp. PMew, Borrelia sp. R57, Borrelia sp. strain Spain, Borrelia sp. TA1, Borrelia sp. TM, Borrelia sp. TM1 and Borrelia sp. TM2.

### Claim 40

The panel according to any of the preceding claims, wherein said panel further comprises one or more negative control MHC multimers.

### Claim 41

The panel according to any of the preceding claims, wherein said panel further comprises one or more negative control MHC multimers wherein each MHC multimer comprises a negative control peptide P.

### Claim 42

The panel according to any of the preceding claims, wherein said negative control peptide P is a nonsense peptide.

### Claim 43

The panel according to any of the preceding claims, wherein said negative control peptide P is a nonsense chemically modified peptide.

### Claim 44

The panel according to any of the preceding claims, wherein said negative control peptide P is a naturally occurring peptide different from the peptide used for analysis of specific T cells in the sample.

### Claim 45

The panel according to any of the preceding claims, wherein said negative control peptide P is a peptide which is not derived from a Borrelia antigenic polypeptide.

### Claim 46

The panel according to any of the preceding claims, wherein said negative control peptide P is a peptide which is not derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 47

The panel according to any of the preceding claims, wherein said one or more negative control MHC multimers are empty MHC multimers.

### Claim 48

The panel according to any of the preceding claims, wherein said panel further comprises one or more positive control MHC multimers.

### Claim 49

The panel according to any of the preceding claims, wherein said panel further comprises one or more positive control MHC multimers wherein each MHC multimer comprises a positive control peptide P.

### Claim 50

A panel comprising one or more pools of MHC multimers comprising (a-b-P)n,
wherein n>1,
wherein polypeptides a and b together form a functional MHC protein capable of binding peptide P, and (a-b-P) is a MHC-peptide complex formed when peptide P binds to the functional MHC protein,
wherein each MHC-peptide complex of a MHC multimer is associated with one or more multimerization domains;
wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 51

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 52

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers, wherein each pool comprises two or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 53

The panel according to any of the preceding claims, comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 54

The panel according to any of the preceding claims, comprising two or more pools of MHC multimers, wherein each pool comprises two or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 55

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers, such as 1 pool of MHC multimers, for example 2 pools of MHC multimers, such as 3 pools of MHC multimers, for example 4 pools of MHC multimers, such as 5 pools of MHC multimers, for example 6 pools of MHC multimers, such as 7 pools of MHC multimers, for example 8 pools of MHC multimers such as 9 pools of MHC multimers, for example 10 pools of MHC multimers, wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 56

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers,
wherein each pool comprises one or more MHC multimers, for example 2 or more MHC multimers, such as 3 or more MHC multimers, for example 4 or more MHC multimers, such as 5 or more MHC multimers, for example 6 or more MHC multimers, such as 7 or more MHC multimers, for example 8 or more MHC multimers such as 9 or more MHC multimers, for example 10 or more MHC multimers, for example 11 or more MHC multimers, such as 12 or more MHC multimers, for example 13 or more MHC multimers, such as 14 or more MHC multimers, for example 15 or more MHC multimers, such as 16 or more MHC multimers, for example 17 or more MHC multimers such as 18 or more MHC multimers, for example 19 or more MHC multimers, for example 20 or more MHC multimers,
wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 57

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers,
wherein each pool comprises one or more MHC multimers, such as 1 MHC multimer, for example 2 MHC multimers, such as 3 MHC multimers, for example 4 MHC multimers, such as 5 MHC multimers, for example 6 MHC multimers, such as 7 MHC multimers, for example 8 MHC multimers such as 9 MHC multimers, for example 10 MHC multimers, for example 11 MHC multimers, such as 12 MHC multimers, for example 13 MHC multimers, such as 14 MHC multimers, for example 15 MHC multimers, such as 16 MHC multimers, for example 17 MHC multimers such as 18 MHC multimers, for example 19 MHC multimers, for example 20 MHC multimers,
wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 58

The panel according to any of the preceding claims, comprising one or more pools of MHC multimers, such as 1 pool of MHC multimers, for example 2 pools of MHC multimers, such as 3 pools of MHC multimers, for example 4 pools of MHC multimers, such as 5 pools of MHC multimers, for example 6 pools of MHC multimers, such as 7 pools of MHC multimers, for example 8 pools of MHC multimers such as 9 pools of MHC multimers, for example 10 pools of MHC multimers,
wherein each pool comprises one or more MHC multimers, such as 1 MHC multimer, for example 2 MHC multimers, such as 3 MHC multimers, for example 4 MHC multimers, such as 5 MHC multimers, for example 6 MHC multimers, such as 7 MHC multimers, for example 8 MHC multimers such as 9 MHC multimers, for example 10 MHC multimers, for example 11 MHC multimers, such as 12 MHC multimers, for example 13 MHC multimers, such as 14 MHC multimers, for example 15 MHC multimers, such as 16 MHC multimers, for example 17 MHC multimers such as 18 MHC multimers, for example 19 MHC multimers, for example 20 MHC multimers,
wherein each MHC multimer comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 59

The panel according to any of the preceding claims comprising one pool of MHC multimers, wherein said pool comprises one MHC multimer comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42 as defined in any one of the preceding claims.

### Claim 60

The panel according to any of the preceding claims comprising one pool of MHC multimers, wherein said pool comprises two or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42 as defined in any one of the preceding claims.

### Claim 61

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each of said two or more pools comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42 as defined in any one of the preceding claims.

### Claim 62

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of
i) OppA (SEQ ID NOs:1-9),
ii) DbpA (SEQ ID NOs:10-20),
iii) FlhF (SEQ ID NOs:21-28),
iv) FlaB (SEQ ID NOs:29-37), and/or
v) P37-42 (SEQ ID NOs:38-39).

### Claim 63

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising
i) an antigenic peptide P derived from Borrelia antigenic polypeptide OppA, such as OppA (SEQ ID NOs:1-9);
ii) an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA, such as DbpA (SEQ ID NOs:10-20);
iii) an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF, such as FlhF (SEQ ID NOs:21-28);
iv) an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB, such as FlaB (SEQ ID NOs:29-37); and/or
v) an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42, such as P37-42 (SEQ ID NOs:38-39).

### Claim 64

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising
i) an antigenic peptide P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20),
ii) an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19),
iii) an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20),
iv) an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and/or
v) an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20).

### Claim 65

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising
i) an antigenic peptide P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20), and including at least one or both of YLNTKSNGNYEI (SEQ ID NO: 359) and FLSIFTQGYT (SEQ ID NO: 241);
ii) an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19), and including at least GIYDLILNA (SEQ ID NO: 2761);
iii) an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20), and including at least YIKDINEFI (SEQ ID NO: 4479);
iv) an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and including at least one or more of IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112); and/or
v) an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20), and including at least one or more of MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 66

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising
i) an antigenic peptide P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A-1, Table A-2, Table A-3, Table A-4, Table A-5, Table A-6, Table A-7, Table A-8, Table A-9, Table A-10, Table A-11, Table A-12, Table A-13, Table A-14, Table A-15, table A-16, Table A-17, Table A-18, Table A-19, or Table A-20,
ii) an antigenic peptide P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B-1, Table B-2, Table B-3, Table B-4, Table B-5, Table B-6, Table B-7, Table B-8, Table B-9, Table B-10, Table B-11, Table B-12, Table B-13, Table B-14, Table B-15, table B-16, Table B-17, Table B-18, or Table B-19,
iii) an antigenic peptide P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C-1, Table C-2, Table C-3, Table C-4, Table C-5, Table C-6, Table C-7, Table C-8, Table C-9, Table C-10, Table C-11, Table C-12, Table C-13, Table C-14, Table C-15, table C-16, Table C-17, Table C-18, Table C-19, or Table C-20,
iv) an antigenic peptide P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D-1, Table D-2, Table D-3, Table D-4, Table D-5, Table D-6, Table D-7, Table D-8, Table D-9, Table D-10, Table D-11, Table D-12, Table D-13, Table D-14, Table D-15, table D-16, Table D-17, Table D-18, Table D-19, or Table D-20, and/or
v) an antigenic peptide P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E-1, Table E-2, Table E-3, Table E-4, Table E-5, Table E-6, Table E-7, Table E-8, Table E-9, Table E-10, Table E-11, Table E-12, Table E-13, Table E-14, Table E-15, table E-16, Table E-17, Table E-18, Table E-19, or Table E-20.

### Claim 67

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42,
i) wherein one of said two or more pools comprises an MHC multimer comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
ii) wherein one of said two or more pools comprises 2 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
iii) wherein one of said two or more pools comprises 3 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
iv) wherein one of said two or more pools comprises 4 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
v) wherein one of said two or more pools comprises 5 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
vi) wherein one of said two or more pools comprises 6 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
vii) wherein one of said two or more pools comprises 7 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
viii) wherein one of said two or more pools comprises 8 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
ix) wherein one of said two or more pools comprises 9 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
x) wherein one of said two or more pools comprises 10 MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42

### Claim 68

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42,
wherein one of said two or more pools comprises one or more MHC multimers each comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; and/or
wherein one of said two or more pools comprises 2 or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from Borrelia antigenic polypeptide selected from the group consisting of:
OppA and DbpA,
OppA and FlhF,
OppA and FlaB,
OppA and P37-42,
DbpA and FlhF,
DbpA and FlaB,
DbpA and P37-42,
FlhF and FlaB,
FlhF and P37-42, or
FlaB and P37-42; and/or
wherein one of said two or more pools comprises 3 or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from Borrelia antigenic polypeptide selected from the group consisting of:
OppA, DbpA and FlhF,
OppA, DbpA and FlaB,
OppA, DbpA and P37-42,
OppA, FlhF and FlaB,
OppA, FlhF and P37-42,
OppA, FlaB and P37-42,
DbpA, FlhF and FlaB,
DbpA, FlhF and P37-42, or
FlhF, FlaB and P37-42; and/or
wherein one of said two or more pools comprises 4 or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from Borrelia antigenic polypeptide selected from the group consisting of:
OppA, DbpA, FlhF and FlaB,
OppA, DbpA, FlhF, P37-42,
OppA, FlhF, FlaB and P37-42,
OppA, DbpA, FlaB and P37-42,
OppA, DbpA, FlhF and P37-42, or
DbpA, FlhF, FlaB and P37-42; and/or
wherein one of said two or more pools comprises 5 or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from Borrelia antigenic polypeptide each derived from Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 69

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein one or more of said pools comprises one or more MHC multimers each MHC multimer comprising an antigenic peptide P selected from the group consisting of
i) antigenic peptides P selected from the group consisting of YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), and YIKDINEFI (SEQ ID NO: 4479),
ii) antigenic peptides P selected from the group consisting of IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112), and/or
iii) antigenic peptides P selected from the group consisting of IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 70

The panel according to any of the preceding claims comprising two or more pools of MHC multimers, wherein one or more of said pools comprises one or more MHC multimers each MHC multimer comprising an antigenic peptide P selected from the group consisting of YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEFI (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127), SQGGVNSPV (SEQ ID NO: 5112), IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 71

The panel according to any of the preceding claims comprising 3 pools of MHC multimers, wherein
i) Pool 1 comprises one or more MHC multimers comprising YLNTKSNGNYEI(SEQ ID NO: 359), one or more MHC multimers comprising FLSIFTQGYT (SEQ ID NO: 241), one or more MHC multimers comprising GIYDLILNA (SEQ ID NO: 2761), and one or more MHC multimers comprising YIKDINEFI (SEQ ID NO: 4479),
ii) Pool 2 comprises one or more MHC multimers comprising IQIEIEQLTDEI (SEQ ID NO: 5126), one or more MHC multimers comprising RMISDQRANLGA (SEQ ID NO: 5127) and one or more MHC multimers comprising SQGGVNSPV (SEQ ID NO: 5112), and
iii) Pool 3 comprises one or more MHC multimers comprising MLDEAKDKL (SEQ ID NO: 5516), one or more MHC multimers comprising FMEQATNSWI (SEQ ID NO: 5530), one or more MHC multimers comprising NLVFSSLFL (SEQ ID NO: 5510) and one or more MHC multimers comprising KLAESIYKRL (SEQ ID NO: 5531).

### Claim 72

The panel according to any of the preceding claims comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers each MHC multimer comprising an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42,
wherein said panel further comprises one or more pools of control MHC multimers, such as one or more pools of negative control MHC multimers and/or one or more pools of positive control MHC multimers.

### Claim 73

The panel according to any of the preceding claims, wherein said panel further comprises one or more pools of negative control MHC multimers.

### Claim 74

The panel according to any of the preceding claims, wherein said panel further comprises one or more pools of negative control MHC multimers wherein each MHC multimer comprises a negative control peptide P.

### Claim 75

The panel according to any of the preceding claims, wherein said negative control peptide P is a nonsense peptide.

### Claim 76

The panel according to any of the preceding claims, wherein said negative control peptide P is a nonsense chemically modified peptide.

### Claim 77

The panel according to any of the preceding claims, wherein said negative control peptide P is a naturally occurring peptide different from the peptide used for analysis of specific T cells in the sample.

### Claim 78

The panel according to any of the preceding claims, wherein said negative control peptide P is a peptide which is not derived from a Borrelia antigenic polypeptide.

### Claim 79

The panel according to any of the preceding claims, wherein said negative control peptide P is a peptide which is not derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 80

The panel according to any of the preceding claims, wherein said negative control MHC multimer comprises peptide ALIAPVHAV (SEQ ID NO: 5913).

### Claim 81

The panel according to any of the preceding claims, wherein said one or more negative control MHC multimers are empty MHC multimers.

### Claim 82

The panel according to any of the preceding claims, wherein said panel further comprises one or more pools of positive control MHC multimers.

### Claim 83

The panel according to any of the preceding claims, wherein said panel further comprises one or more pools of positive control MHC multimers, wherein each MHC multimer comprises a positive control peptide P.

### Claim 84

The panel according to any of the preceding claims, wherein said positive control MHC multimer comprises a peptide selected from the group consisting of NLVPMVATV (SEQ ID NO: 5914), GLCTLVAML (SEQ ID NO: 5915) and GILGFVFTL (SEQ ID NO: 5916).

### Claim 85

The panel according to any of the preceding claims comprising 5 pools of MHC multimers, wherein
i) Pool 1 comprises one or more MHC multimers comprising YLNTKSNGNYEI (SEQ ID NO: 359), one or more MHC multimers comprising FLSIFTQGYT (SEQ ID NO: 241), one or more MHC multimers comprising GIYDLILNA (SEQ ID NO: 2761), and one or more MHC multimers comprising YIKDINEFI (SEQ ID NO: 4479),
ii) Pool 2 comprises one or more MHC multimers comprising IQIEIEQLTDEI (SEQ ID NO: 5126), one or more MHC multimers comprising RMISDQRANLGA (SEQ ID NO: 5127) and one or more MHC multimers comprising SQGGVNSPV (SEQ ID NO: 5112),
iii) Pool 3 comprises one or more MHC multimers comprising MLDEAKDKL (SEQ ID NO: 5516), one or more MHC multimers comprising FMEQATNSWI (SEQ ID NO: 5530), one or more MHC multimers comprising NLVFSSLFL (SEQ ID NO: 5510) and one or more MHC multimers comprising KLAESIYKRL (SEQ ID NO: 5531),
iv) Pool 4 comprises one or more negative control MHC multimers, and
v) Pool 5 comprises one or more positive control MHC multimers.

### Claim 86

The panel according to any of the preceding claims comprising 5 pools of MHC multimers, wherein
i) Pool 1 comprises one or more MHC multimers comprising YLNTKSNGNYEI (SEQ ID NO: 359), one or more MHC multimers comprising FLSIFTQGYT (SEQ ID NO: 241), one or more MHC multimers comprising GIYDLILNA (SEQ ID NO: 2761), and one or more MHC multimers comprising YIKDINEFI (SEQ ID NO: 4479),
ii) Pool 2 comprises one or more MHC multimers comprising IQIEIEQLTDEI (SEQ ID NO: 5126), one or more MHC multimers comprising RMISDQRANLGA (SEQ ID NO: 5127) and one or more MHC multimers comprising SQGGVNSPV (SEQ ID NO: 5112),
iii) Pool 3 comprises one or more MHC multimers comprising MLDEAKDKL (SEQ ID NO: 5516), one or more MHC multimers comprising FMEQATNSWI (SEQ ID NO: 5530), one or more MHC multimers comprising NLVFSSLFL (SEQ ID NO: 5510) and one or more MHC multimers comprising KLAESIYKRL (SEQ ID NO: 5531),
iv) Pool 4 comprises one or more MHC multimers comprising ALIAPVHAV (SEQ ID NO: 5913), and
v) Pool 5 comprises one or more MHC multimers comprising NLVPMVATV (SEQ ID NO: 5914), one or more MHC multimers comprising GLCTLVAML (SEQ ID NO: 5915) and one or more MHC multimers comprising GILGFVFTL (SEQ ID NO: 5916).

### Claim 87

The panel comprising one or more MHC multimers, or the panel comprising one or more pools of MHC multimers according to any of the preceding claims, wherein the individual antigenic peptides P of each MHC-peptide complex of said MHC multimer are identical.

### Claim 88

The panel comprising one or more MHC multimers, or the panel comprising one or more pools of MHC multimers according to any of the preceding claims, wherein the individual antigenic peptides P of each MHC-peptide complex of said MHC multimer are different.

### Claim 89

The panel comprising one or more MHC multimers, or the panel comprising one or more pools of MHC multimers according to any of the preceding claims, wherein some of the individual antigenic peptides P of each MHC-peptide complex of said MHC multimer are identical and some are different.

### Claim 90

The panel comprising one or more MHC multimers, or the panel comprising one or more pools of MHC multimers according to any of the preceding claims, wherein the individual antigenic peptides P of each MHC-peptide complex of said MHC multimer are identical or different, wherein each antigenic peptide P are derived from the same Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 91

The panel comprising one or more MHC multimers, or the panel comprising one or more pools of MHC multimers according to any of the preceding claims, wherein the individual antigenic peptides P of each MHC-peptide complex of said MHC multimer are identical or different, wherein each antigenic peptide P are derived from one or more different Borrelia antigenic polypeptides selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 92

The panel according to any of the previous claims, wherein the value of n of said one or more MHC multimers comprising (a-b-P)n, is 1<n≥1000, such as between 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20-21, 21-22, 22-23, 23-24, 24-25, 25-26, 26-27, 27-28, 28-29, 29-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 75-80, 80-85, 85-90, 90-95, 95-100, 100-110, 110-120, 120-130, 130-140, 140-150,150-160, 160-170, 170-180, 180-190, 190-200, 200-225, 225-250, 250-275, 275-300, 300-325, 325-350, 350-375, 375-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000.

### Claim 93

The panel according to any of the previous claims, wherein the value of n of said one or more MHC multimers comprising (a-b-P)n, is >1, such as 2, such as >2, such as ≥2, such as 3, such as >3, such as ≥3, such as 4, such as >4, such as ≥4, such as 5, such as >5, such as ≥5, such as 6, such as >6, such as ≥6, such as 7, such as >7, such as ≥7, such as 8, such as >8, such as ≥8, such as 9, such as >9, such as ≥9, such as 10, such as >10, such as ≥10.

### Claim 94

The panel according to any of the previous claims, wherein said MHC protein is MHC Class I.

### Claim 95

The panel according to any of the previous claims, wherein said MHC protein is MHC Class I and the antigenic peptides P are selected from the group consisting of 8-, 9-, 10,- 11-, and 12-mer peptides that binds to MHC Class I.

### Claim 96

The panel according to any of the previous claims, wherein said MHC protein is selected from the group of HLA alleles consisting of:
A*01010101B*070201Cw*010201E*01010101F*01010101G*01010101, A*01010102NB*070202Cw*010202E*01010102F*01010102G*01010102, A*010102B*070203Cw*010203E*01010103F*01010103G*01010103, A*010103B*070204Cw*010204E*01030101F*01010104G*01010104, A*010104B*0703Cw*0103E*01030102F*01010105G*01010105, A*0102B*0704Cw*0104E*010302F*01010106G*01010201, A*0103B*070501Cw*0105E*010303F*01010107G*01010202, A*0104NB*070502Cw*0106E*010304F*01010108G*010103, A*0106B*070503Cw*0107E*0104F*01010201G*010104, A*0107B*0706Cw*0108F*01010202G*010105, A*0108B*0707Cw*0109F*01010203G*010106, A*0109B*0708Cw*0110F*01010204G*010107, A*0110B*0709Cw*0111F*01010205G*010108, A*0111NB*0710Cw*0112F*01010301G*010109, A*0112B*0711 Cw*0113F*01010302G*010110, A*0113B*0712Cw*020201F*01010303G*0102, A*0114B*0713Cw*020202F*01010304G*0103, A*0115NB*0714Cw*020203F*0102G*010401, A*0116NB*0715Cw*020205F*01030101G*010402, A*0117B*0716Cw*0203F*01030102G*010403, A*0118NB*0717Cw*0204F*0104G*0105N, A*0119B*0718Cw*0205G*0106, A*0120B*0719Cw*0206G*0107, A*02010101 B*0720Cw*0207, A*02010102LB*0721Cw*0208, A*020102B*0722Cw*0209, A*020103B*0723Cw*0210, A*020104B*0724Cw*0211, A*020105B*0725Cw*0212, A*020106B*0726Cw*0213, A*020107B*0727Cw*0214, A*020108B*0728Cw*0215, A*020109B*0729Cw*0216, A*020110B*0730Cw*0217, A*020111B*0731Cw*030201, A*020112B*0732Cw*030202, A*0202B*0733Cw*030301, A*020301B*0734Cw*030302, A*020302B*0735Cw*030303, A*0204B*0736Cw*030304, A*0205B*0737Cw*030305, A*020601B*0738Cw*030401, A*020602B*0739Cw*030402, A*020603B*0740Cw*030403, A*0207B*0741Cw*030404, A*0208B*0742Cw*030405, A*0209B*0743Cw*0305, A*0210B*0744Cw*0306, A*0211 B*0745Cw*0307, A*0212B*0746Cw*0308, A*0213B*0747Cw*0309, A*0214B*0748Cw*0310, A*0215NB*0749NCw*031101, A*0216B*0750Cw*031102, A*021701 B*0751Cw*0312, A*021702B*080101Cw*0313, A*0218B*080102Cw*0314, A*0219B*080103Cw*0315, A*022001 B*0802Cw*0316, A*022002B*0803Cw*0317, A*0221 B*0804Cw*0318, A*0222B*0805Cw*0319, A*0224B*0806Cw*0320N, A*0225B*0807Cw*0321, A*0226B*0808NCw*0322Q, A*0227B*0809Cw*0323, A*0228B*0810Cw*0324, A*0229B*0811Cw*0325, A*0230B*0812Cw*0326, A*0231B*0813Cw*0327, A*0232NB*0814Cw*0328, A*0233B*0815Cw*0329, A*0234B*0816Cw*0330, A*023501B*0817Cw*0331, A*023502B*0818Cw*0332, A*0236B*0819NCw*0333, A*0237B*0820Cw*0334, A*0238B*0821Cw*0335, A*0239B*0822Cw*04010101, A*0240B*0823Cw*04010102, A*0241 B*0824Cw*040102, A*0242B*0825Cw*040103, A*0243NB*0826Cw*040104, A*0244B*0827Cw*0403, A*0245B*0828Cw*040401, A*0246B*0829Cw*040402, A*0247B*0830NCw*0405, A*0248B*0831Cw*0406, A*0249B*1301Cw*0407, A*0250B*130201Cw*0408, A*0251B*130202Cw*0409N, A*0252B*130203Cw*0410, A*0253NB*1303Cw*0411, A*0254B*1304Cw*0412, A*0255B*1306Cw*0413, A*0256B*1307NCw*0414, A*0257B*1308Cw*0415, A*0258B*1309Cw*0416, A*0259B*1310Cw*0417, A*0260B*1311Cw*0418, A*0261B*1312Cw*0419, A*0262B*1313Cw*0420, A*0263B*1314Cw*0421, A*0264B*1315Cw*0423, A*0265B*1316Cw*0424, A*0266B*1317Cw*050101, A*0267B*1401Cw*050102, A*0268B*140201Cw*050103, A*0269B*140202Cw*0502, A*0270B*1403Cw*0503, A*0271B*1404Cw*0504, A*0272B*1405Cw*0505, A*0273B*140601Cw*0506, A*027401B*140602Cw*0507N, A*027402B*1407NCw*0508, A*0275B*15010101Cw*0509, A*0276B*15010102NCw*0510, A*0277B*150102Cw*0511, A*0278B*150103Cw*0512, A*0279B*150104Cw*0513, A*0280B*1502Cw*0514, A*0281B*1503Cw*0515, A*0282NB*1504Cw*06020101, A*0283NB*1505Cw*06020102, A*0284B*1506Cw*060202, A*0285B*1507Cw*0603, A*0286B*1508Cw*0604, A*0287B*1509Cw*0605, A*0288NB*1510Cw*0606, A*0289B*151101Cw*0607, A*0290B*151102Cw*0608, A*0291B*151103Cw*0609, A*0292B*1512Cw*0610, A*0293B*1513Cw*0611, A*0294NB*1514Cw*0612, A*0295B*1515Cw*0613, A*0296B*1516Cw*0614, A*0297B*15170101Cw*070101, A*0299B*15170102Cw*070102, A*03010101B*151702Cw*070103, A*03010102NB*1518Cw*070104, A*03010103B*1519Cw*070105, A*030102B*1520Cw*070106, A*030103B*1521Cw*070107, A*030104B*1523Cw*07020101, A*030105B*1524Cw*07020102, A*0302B*1525Cw*07020103, A*0303NB*1526NCw*0703, A*0304B*1527Cw*070401, A*0305B*1528Cw*070402, A*0306B*1529Cw*0705, A*0307B*1530Cw*0706, A*0308B*1531Cw*0707, A*0309B*1532Cw*0708, A*0310B*1533Cw*0709, A*0311NB*1534Cw*0710, A*0312B*1535Cw*0711, A*0313B*1536Cw*0712, A*0314B*1537Cw*0713, A*0315B*1538Cw*0714, A*0316B*1539Cw*0715, A*0317B*1540Cw*0716, A*0318B*1542Cw*0717, A*0319B*1543Cw*0718, A*0320B*1544Cw*0719, A*0321NB*1545Cw*0720, A*0322B*1546Cw*0721, A*0323B*1547Cw*0722, A*0324B*1548Cw*0723, A*0325B*1549Cw*0724, A*0326B*1550Cw*0725, A*110101B*1551Cw*0726, A*110102B*1552Cw*0727, A*110103B*1553Cw*0728, A*110104B*1554Cw*0729, A*110105B*1555Cw*0730, A*110106B*1556Cw*0731, A*110201B*1557Cw*0732N, A*110202B*1558Cw*0733N, A*1103B*1560Cw*0734, A*1104B*1561Cw*0735, A*1105B*1562Cw*0736, A*1106B*1563Cw*0737, A*1107B*1564Cw*0738, A*1108B*1565Cw*0739, A*1109B*1566Cw*0740, A*1110B*1567Cw*0741, A*111B*1568Cw*0742, A*1112B*1569Cw*0743, A*1113B*1570Cw*0744, A*1114B*1571Cw*0745, A*1115B*1572Cw*080101, A*1116B*1573Cw*080102, A*1117B*1574Cw*0802, A*1118B*1575Cw*0803, A*1301 B*1576Cw*0804, A*1120B*1577Cw*0805, A*1121NB*1578Cw*0806, A*1122B*1579NCw*0807, A*1123B*1580Cw*0808, A*1124B*1581Cw*0809, A*1125B*1582Cw*0810, 50 A*1126B*1583Cw*0811, A*1127B*1584Cw*0812, A*1128B*1585Cw*0813, A*1129B*1586Cw*0814, A*2301B*1587Cw*120201, A*2302B*1588Cw*120202, A*2303B*1589Cw*120203, A*2304B*1590Cw*12030101, A*2305B*1591Cw*12030102, A*2306B*1592Cw*120302, A*2307NB*1593Cw*120303, A*2308NB*1594NCw*120304, A*2309B*1595Cw*120401, A*2310B*1596Cw*120402, A*2311NB*1597Cw*1205, A*2312B*1598Cw*1206, A*2313B*1599Cw*1207, A*2314B*9501Cw*1208, A*24020101B*9502Cw*1209, A*24020102LB*9503Cw*1210, A*240202B*9504Cw*1211, A*240203B*9505Cw*1212, A*240204B*9506Cw*1213, A*240205B*9507Cw*1214, A*240206B*9508Cw*1215, A*240207B*9509Cw*1216, A*240208B*9510Cw*1217, A*240209B*9511NCw*1218, A*240210B*9512Cw*1219, A*240211B*9513Cw*140201, A*240212B*9514Cw*140202, A*240213B*9515Cw*140203, A*240301 B*9516Cw*140204, A*240302B*9517Cw*1403, A*2404B*9518Cw*1404, A*2405B*9519Cw*1405, A*2406B*9520Cw*1406, A*2407B*9521Cw*1407N, A*2408B*9522Cw*1408, A*2409NB*180101Cw*150201, A*2410B*180102Cw*150202, A*2411NB*180103Cw*150203, A*2413B*1802Cw*1503, A*2414B*1803Cw*1504, A*2415B*1804Cw*150501, A*2417B*1805Cw*150502, A*2418B*1806Cw*150503, A*2419B*1807Cw*150504, A*2420B*1808Cw*1506, A*2421 B*1809Cw*1507, A*2422B*1810Cw*1508, A*2423B*1811Cw*1509, A*2424B*1812Cw*1510, A*2425B*1813Cw*1511, A*2426B*1814Cw*1512, A*2427B*1815Cw*1513, A*2428B*1817NCw*1514, A*2429B*1818Cw*1515, A*2430B*1819Cw*1516, A*2431B*1820Cw*1517, A*2432B*1821Cw*160101, A*2433B*1822Cw*160102, A*2434B*1823NCw*1602, A*2435B*1824Cw*160401, A*2436NB*2701Cw*1606, A*2437B*2702Cw*1607, A*2438B*2703Cw*1608, A*2439B*270401Cw*1609, A*2440NB*270402Cw*1701, A*2441B*270502Cw*1702, A*2442B*270503Cw*1703, A*2443B*270504Cw*1704, A*2444B*270505Cw*1801, A*2445NB*270506Cw*1802, A*2446B*270507, A*2447B*270508, A*2448NB*270509, A*2449B*2706, A*2450B*2707, A*2451B*2708, A*2452B*2709, A*2453B*2710, A*2454B*2711, A*2455B*2712, A*2456B*2713, A*2457B*2714, A*2458B*2715, A*2459B*2716, A*2460NB*2717, A*2461B*2718, A*2462B*2719, A*2463B*2720, A*2464B*2721, A*2465B*2723, A*2466B*2724, A*2467B*2725, A*2468B*2726, A*250101B*2727, A*250102B*2728, A*2502B*2729, A*2503B*2730, A*2504B*2731, A*2505B*2732, A*2506B*2733, A*260101 B*2734, A*260102B*2735, A*260103B*2736, A*260104B*350101, A*2602B*350102, A*2603B*350103, A*2604B*350104, A*2605B*350105, A*2606B*350106, A*260701B*350201, A*260702B*350202, A*2608B*3503, A*2609B*350401, A*2610B*350402, A*2611NB*3505, A*2612B*3506, A*2613B*3507, A*2614B*350801, A*2615B*350802, A*2616B*350901, A*2617B*350902, A*2618B*3510, A*2619B*3511, A*2620B*3512, A*2621B*3513, A*2622B*351401, A*2623B*351402, A*2624B*3515, A*2625NB*3516, A*2626B*3517, A*2627B*3518, A*2628B*3519, A*2629B*3520, A*2630B*3521, A*2631B*3522, A*2632B*3523, A*2633B*3524, A*2634B*3525, A*29010101B*3526, A*29010102NB*3527, A*290201 B*3528, A*290202B*3529, A*290203B*3530, A*2903B*3531, A*2904B*3532, A*2905B*3533, A*2906B*3534, A*2907B*3535, A*2908NB*3536, A*2909B*3537, A*2910B*3538, A*2911 B*3539, A*2912B*3540N, A*2913B*3541, A*2914B*3542, A*2915B*3543, A*2916B*3544, A*300101B*3545, A*300102B*3546, A*300201B*3547, A*300202B*3548, A*300203B*3549, A*3003B*3550, A*3004B*3551, A*3006B*3552, A*3007B*3553N, A*3008B*3554, A*3009B*3555, A*3010B*3556, A*3011 B*3557, A*3012B*3558, A*3013B*3559, A*3014LB*3560, A*3015B*3561, A*3016B*3562, A*3017B*3563, A*3018B*3564, A*3019B*3565Q, A*310102B*3566, A*3102B*3567, A*3103B*3568, A*3104B*3569, A*3105B*3570, A*3106B*3571, A*3107B*3572, A*3108B*370101, A*3109B*370102, A*3110B*370103, A*3111B*370104, A*3112B*3702, 50 A*3113B*3703N, A*3114NB*3704, A*3115B*3705, A*3201B*3706, A*3202B*3707, A*3203B*3708, A*3204B*3709, A*3205B*3710, A*3206B*3711, A*3207B*3712, A*3208B*380101, A*3209B*380102, A*3210B*380201, A*3211QB*380202, A*3212B*3803, A*3213B*3804, A*3214B*3805, A*3301 B*3806, A*330301 B*3807, A*330302B*3808, A*3304B*3809, A*3305B*3810, A*3306B*3811, A*3307B*3812, A*3308B*3813, A*3309B*3814, A*3401B*3815, A*3402B*39010101, A*3403B*39010102L, A*3404B*390103, A*3405B*390104, A*3406B*390201, A*3407B*390202, A*3408B*3903, A*3601 B*3904, A*3602B*3905, A*3603B*390601, A*3604B*390602, A*4301 B*3907, A*6601 B*3908, A*6602B*3909, A*6603B*3910, A*6604B*3911, A*6605B*3912, A*6606B*391301, A*680101 B*391302, A*680102B*3914, A*680103B*3915, A*680104B*3916, A*680105B*3917, A*68020101 B*3918, A*68020102B*3919, A*680301 B*3920, A*680302B*3922, A*6804B*3923, A*6805B*3924, A*6806B*3925N, A*6807B*3926, A*6808B*3927, A*6809B*3928, A*6810B*3929, A*6811 NB*3930, A*6812B*3931, A*6813B*3932, A*6814B*3933, A*6815B*3934, A*6816B*3935, A*6817B*3936, A*6818NB*3937, A*6819B*3938Q, A*6820B*3939, A*6821B*3940N, A*6822B*3941, A*6823B*400101, A*6824B*400102, A*6825B*400103, A*6826B*400104, A*6827B*400105, A*6828B*400201, A*6829B*400202, A*6830B*400203, A*6831B*4003, A*6832B*4004, A*6833B*4005, A*6834B*40060101, A*6835B*40060102, A*6836B*400602, A*6901 B*4007, A*7401 B*4008, A*7402B*4009, A*7403B*4010, A*7404B*4011, A*7405B*4012, A*7406B*4013, A*7407B*401401, A*7408B*401402, A*7409B*401403, A*7410B*4015, A*7411 B*4016, A*7412NB*4018, A*8001 B*4019, A*9201 B*4020, A*9202B*4021, A*9203B*4022N, A*9204B*4023, A*9205B*4024, A*9206B*4025, A*9207B*4026, A*9208B*4027, A*9209B*4028, B*4029, B*4030, B*4031, B*4032, B*4033, B*4034, B*4035, B*4036, B*4037, B*4038, B*4039, B*4040, B*4042, B*4043, B*4044, B*4045, B*4046, B*4047, B*4048, B*4049, B*4050, B*4051, B*4052, B*4053, B*4054, B*4055, B*4056, B*4057, B*4058, B*4059, B*4060, B*4061, B*4062, B*4063, B*4064, B*4065, B*4066, B*4067, B*4068, B*4069, B*4070, B*4101, B*4102, B*4103, B*4104, B*4105, B*4106, B*4107, B*4108, B*4201, B*4202, B*4204, B*420501, B*420502, B*4206, B*4207, B*4208, B*4209, B*44020101, B*44020102S, B*440202, B*440203, B*440204, B*440301, B*440302, B*4404, B*4405, B*4406, B*4407, B*4408, B*4409, B*4410, B*4411, B*4412, B*4413, B*4414, B*4415, B*4416, B*4417, B*4418, B*4419N, B*4420, B*4421, B*4422, B*4423N, B*4424, B*4425, B*4426, B*4427, B*4428, B*4429, B*4430, B*4431, B*4432, B*4433, B*4434, B*4435, B*4436, B*4437, B*4438, B*4439, B*4440, B*4441, B*4442, B*4443, B*4444, B*4445, B*4446, B*4447, B*4448, B*4449, B*4450, B*4451, B*4501, B*4502, B*4503, B*4504, B*4505, B*4506, B*4507, B*460101, B*460102, B*4602, B*4603, B*4604, B*4605, B*4606, B*4607N, B*4608, B*4609, B*47010101, B*47010102, B*4702, B*4703, B*4704, B*4705, B*4801, B*4802, B*480301, B*480302, B*4804, B*4805, B*4806, B*4807, B*4808, B*4809, B*4810, B*4811, B*4812, B*4813, B*4814, B*4815, B*4816, B*4901, B*4902, B*4903, B*4904, B*4905, B*5001, B*5002, B*5004, B*510101, B*510102, B*510103, B*510104, B*510105, B*510106, B*510107, B*510201, B*510202, B*5103, B*5104, B*5105, B*5106, B*5107, B*5108, B*5109, B*5110, B*5111N, B*5112, B*511301, B*511302, B*5114, B*5115, B*5116, B*5117, B*5118, B*5119, B*5120, B*5121, B*5122, B*5123, B*5124, B*5126, B*5127N, B*5128, B*5129, B*5130, B*5131, B*5132, B*5133, B*5134, B*5135, B*5136, B*5137, B*5138, B*5139, B*5140, B*5141N, B*5142, B*5143, B*5144N, B*5145, B*5146, B*520101, B*520102, B*520103, B*520104, B*5202, B*5203, B*5204, B*5205, B*5206, B*5207, B*5208, B*5209, B*5210, B*530101, B*530102, B*530103, B*530104, B*5302, B*5303, B*5304, B*5305, B*5306, B*5307, B*5308, B*5309, B*5310, B*5311, B*5312, B*5401, B*5402, B*5403, B*5404, B*5405N, B*5406, B*5407, B*5408N, B*5409, 50 B*5410, B*5411, B*5412, B*550101, B*550102, B*550103, B*550104, B*550201, B*550202, B*5503, B*5504, B*5505, B*5507, B*5508, B*5509, B*5510, B*5511, B*5512, B*5513, B*5514, B*5515, B*5516, B*5517, B*5518, B*5519, B*5520, B*5521, B*5522, B*5523, B*5524, B*5601, B*5602, B*5603, B*5604, B*560501, B*560502, B*5606, B*5607, B*5608, B*5609, B*5610, B*5611, B*5612, B*5613, B*5614, B*5615, B*5616, B*5617, B*5618, B*5619N, B*570101, B*570102, B*570103, B*5702, B*570301, B*570302, B*5704, B*5705, B*5706, B*5707, B*5708, B*5709, B*5710, B*5711, B*5801, B*5802, B*5804, B*5805, B*5806, B*5807, B*5808, B*5809, B*5810N, B*5811, B*5812, B*5813, B*5814, B*5901, B*5902, B*670101, B*670102, B*6702, B*7301, B*7801, B*780201, B*780202, B*7803, B*7804, B*7805, B*8101, B*8102, B*8201, B*8202, B*8301, H*01010101J*01010101K*01010101L*01010101P*01010101, H*01010102J*01010102K*01010102L*01010102P*01010102, H*01010103J*01010103K*01010103L*01010103P*02010101, H*0102J*01010104K*01010104L*010102P*02010102, H*02010101J*01010105K*0102L*0102, H*02010102J*01010106K*0103, H*0202J*01010107, H*0203J*01010108, H*0204J*0201, H*0205, H*0206 and, H*0301

### Claim 97

The panel according to any of the previous claims, wherein said MHC protein is selected from the group of HLA alleles consisting of: A*0201, C*0701, A*0101, A*0301, C*0702, C*0401, B*4402, B*0702, B*0801, C*0501, C*0304, C*0602, A*1101, B*4001, A*2402, B*3501, C*0303, B*5101, C*1203, B*1501, A*2902, A*2601, A*3201, C*0802, A*2501, B*5701, B*1402, C*0202, B*1801, B*4403, C*0401, C*0701, C*0602, A*0201, A*2301, C*0202, A*0301, C*0702, B*5301, B*0702, C*1601, B*1503, B*5801, A*6802, C*1701, B*4501, B*4201, A*3001, B*3501, A*0101, C*0304, A*3002, B*0801, A*3402, A*7401, A*3303, C*1801, A*2902, B*4403, B*4901, A*0201, C*0401, A*2402, C*0702, C*0701, C*0304, A*0301, B*0702, B*3501, C*0602, C*0501, A*0101, A*1101, B*5101, C*1601, B*4403, C*0102, A*2902, C*0802, B*1801, A*3101, B*5201, B*1402, C*0202, C*1203, A*2601, A*6801, B*0801, A*3002, B*4402, A*1101, A*2402, C*0702, C*0102, A*3303, C*0801, C*0304, A*0201, B*4001, C*0401, B*5801, B*4601, B*5101, C*0302, B*3802, A*0207, B*1501, A*0206, C*0303, B*1502, A*0203, B*4403, C*1402, B*3501, C*0602, B*5401, B*1301, B*4002, B*5502 and A*2601.

### Claim 98

The panel according to any of the preceding claims, wherein said MHC protein is selected from the group of HLA alleles consisting of: HLA-A*A0101, A0201, A0301, A1101, A2402, A2501, A2601, A2902, A3101, A3201, A6801, B0702, B0801, B1503, B1801, B3501, B4002, B4402, B4501 and B5101.

### Claim 99

The panel according to any of the preceding claims, wherein the antigenic peptides P are selected from the group consisting of 8-, 9-, 10,- 11-, and 12-mer peptides P that binds to MHC Class I and which are derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 100

The panel according to any of the preceding claims, wherein generation, identification or prediction of the antigenic peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42 for a given MHC (HLA) allele comprises computational analysis.

### Claim 101

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises computational analysis using prediction software.

### Claim 102

The panel according to any of the preceding claims, wherein the prediction software is NetMHC (http://www.cbs.dtu.dk/services/NetMHC/).

### Claim 103

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of theoretical binding affinity of the peptide P to the MHC (HLA) molecules.

### Claim 104

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOs:38-39) for a given MHC allele comprises computational analysis of the prediction of theoretical binding affinity of the peptide P to the MHC molecules using the prediction software NetMHC (http://www.cbs.dtu.dk/services/NetMHC/).

### Claim 105

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of a theoretical binding affinity of the peptide P to the one or more MHC Class I alleles with a binding affinity threshold (nM).

### Claim 106

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of a theoretical binding affinity of the peptide P to the one or more MHC Class I molecules with a binding affinity threshold of 1000 nM.

### Claim 107

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of a theoretical binding affinity of the peptide P to the MHC Class I molecules with an affinity threshold of 50 nM, such as 100 nM, such as 150 nM, such as 200 nM, such as 250 nM, such as 300 nM, such as 400 nM, such as 500 nM, such as 600 nM, such as 700 nM, such as 800 nM, such as 900 nM, such as 1000 nM, such as 1250 nM, such as 1500 nM, such as 1750 nM, such as 2000 nM, such as 2500 nM, such as 3000 nM, such as 3500 nM, such as 4000 nM, such as 4500 nM, such as 5000 nM, such as 6000 nM, such as 7000 nM, such as 8000 nM, such as 9000 nM, such as 10000 nM for individual HLA class I alleles.

### Claim 108

The panel according to any of the preceding claims, wherein said antigenic peptides P has a theoretical binding affinity of less than 50 nM, such as 50-100 nM, such as 100-150 nM, such as 150-200 nM, such as 200-250 nM, such as 250-300 nM, such as 300-400 nM, such as 400-500 nM, such as 500-600 nM, such as 600-700 nM, such as 700-800 nM, such as 800-900 nM, such as 900-1000 nM, such as 1000-1250 nM, such as 1250-1500 nM, such as 1500-1750 nM, such as 1750-2000 nM, such as 2000-2500 nM, such as 2500-3000 nM, such as 3000-3500 nM, such as 3500-4000 nM, such as 4000-4500 nM, such as 4500-5000 nM, such as 5000-6000 nM, such as 6000-7000 nM, such as 7000-8000 nM, such as 8000-9000 nM, such as 9000-10000 nM for individual HLA class I alleles.

### Claim 109

The panel according to any of the preceding claims, wherein said antigenic peptides P has a theoretical binding affinity of less than 50 nM (strong binder), or less than 500 nM (weak binder), or less than 1000 nM (binder).

### Claim 110

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of a rank score relative binding strength of the peptide P to the one or more MHC Class I alleles with a relative binding strength threshold (% Rank).

### Claim 111

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37) and P37-42 (SEQ ID NOs:38-39) for a given MHC allele comprises computational analysis of the prediction of a rank score relative binding strength of the peptide P to the one or more MHC Class I alleles with a relative binding strength threshold (% Rank)using the prediction software NetMHC (http://www.cbs.dtu.dk/services/NetMHC/).

### Claim 112

The panel according to any of the preceding claims, wherein identification of the antigenic peptides P comprises prediction of the relative binding strength of the peptide P to the one or more MHC Class I alleles with a threshold of 0.5% Rank, such as 1% Rank, such as 1,5% Rank, such as 2% Rank.

### Claim 113

The panel according to any of the preceding claims, wherein said antigenic peptides P has a rank score relative binding strength of less than 0.5% Rank, such as 0,5-1% Rank, such as 1-1,5% Rank, such as 1,5-2, such as 2-2,5, such as 2,5-3, such as 3-3,5 such as 3,5-4, such as 4-4,5, such as 4,5-5% Rank.

### Claim 114

The panel according to any of the preceding claims, wherein said antigenic peptide P is selected from the sequences included in Tables A to E herein above (Tables A1-A20, B1-B19, C1-C20, D1-D20 and E1-E20).

### Claim 115

The panel according to any of the preceding claims, wherein said antigenic peptide P comprises or consists of a modified sequence obtained by modification of said antigenic peptide P.

### Claim 116

The panel according to any of the preceding claims, wherein said antigenic peptide P comprises or consists of a modified sequence obtained by modification of a sequence selected from the sequences included in Tables A to E herein above (Tables A1-A20, B1-B19, C1-C20, D1-D20 and E1-E20).

### Claim 117

The panel according to any of the preceding claims, wherein said modified antigenic peptide P has at least 50%, such as at least 60%, such as at least 70%, such as at least 85%, such as at least 95% or such as at least 99% sequence identity with a sequence included in Tables A to E herein above (Tables A1-A20, B1-B19, C1-C20, D1-D20 and E1-E20).

### Claim 118

The panel according to any of the preceding claims, wherein said modified antigenic peptide P has one or more amino acid substitutions, such as 1 amino acid substitution, such as 2 amino acid substitutions, such as 3 amino acid substitutions, such as 4 amino acid substitutions, such as 5 amino acid substitutions, such as 6 amino acid substitutions.

### Claim 119

The panel according to any of the preceding claims, wherein said modified antigenic peptide P has one or more equivalent amino acid substitutions.

### Claim 120

The panel according to any of the preceding claims, wherein said modified antigenic peptide P has one or more non-equivalent amino acid substitutions.

### Claim 121

The panel according to any of the preceding claims, wherein said antigenic peptide P or modified antigenic peptide P comprises an anchor motif selected from the group of HLA motifs included in Table I herein above.

### Claim 122

The panel according to any of the preceding claims, wherein said antigenic peptide P or modified antigenic peptide P comprises a primary anchoring amino acid residue in amino acid position 2 and/or 9 in accordance with Table I herein above.

### Claim 123

The panel according to any of the preceding claims, wherein said antigenic peptide P or modified antigenic peptide P comprises a substitution of the amino acid residue in position 2 with an amino acid residue selected from the group consisting of:
i) alanine, threonine, serine, valine, leucine, isoleucine, methionine, glutamine, phenylalanine, tryptophan and tyrosine,
ii) alanine, threonine, serine, valine, leucine, isoleucine, methionine and glutamine iii) arginine, histidine and lysine,
iv) aspartic acid and glutamic acid, or
v) alanine, threonine and serine.

### Claim 124

The panel according to any of the preceding claims, wherein said antigenic peptide P or modified antigenic peptide P comprises a substitution of the amino acid residue in position 9 or 10 with an amino acid residue selected from the group consisting of:
i) phenylalanine, tryptophan, tyrosine, leucine, isoleucine, valine, glutamine, alanine, argentine, histidine, lysine and methionine,
ii) phenylalanine, tryptophan, tyrosine, leucine, isoleucine, valine, glutamine, alanine and methionine,
iii) leucine, isoleucine, valine, glutamine, alanine and methionine,
iv) phenylalanine, tryptophan, tyrosine, leucine, isoleucine and methionine
v) glutamine and alanine, and
vi) tyrosine, arginine and lysine.

### Claim 125

The panel according to any of the preceding claims, wherein the association between the one or more of each MHC protein or MHC-peptide complex of a multimeric MHC, and the one or more multimerization domains, is a covalent association.

### Claim 126

The panel according to any of the preceding claims, wherein the association between the one or more of each MHC protein or MHC-peptide complex of a multimeric MHC, and the one or more multimerization domains, is a non-covalent association.

### Claim 127

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more multimerization domain connector molecules.

### Claim 128

The panel according to any of the preceding claims, wherein one or more of each MHC protein or MHC-peptide complex of a multimeric MHC comprises one or more MHC connector molecules.

### Claim 129

The panel according to any of the preceding claims, wherein the one or more multimerization domain connector molecules comprises one or more streptavidins and/or one or more avidins, or any derivatives thereof.

### Claim 130

The panel according to any of the preceding claims, wherein the one or more streptavidins comprises one or more tetrameric streptavidin variants or one or more monomeric streptavidin variants.

### Claim 131

The panel according to any of the preceding claims, wherein the one or more MHC connector molecules is biotin.

### Claim 132

The panel according to any of the preceding claims, wherein one or more of each MHC protein or MHC-peptide complex of a MHC multimer is associated with one or more multimerization domains via a streptavidin-biotin linkage or an avidin-biotin linkage.

### Claim 133

The panel according to any of the preceding claims, wherein one or more of each MHC protein or MHC-peptide complex of a MHC multimer is associated with one or more multimerization domains by a linker moiety.

### Claim 134

The panel according to any of the preceding claims, wherein one or more of each MHC protein or MHC-peptide complex of a MHC multimer is associated with one or more multimerization domains by a natural dimerization and/or a protein-protein interaction, such as selected from the group consisting of leucine zipper e.g. leucine zipper domain of AP-1, Fos/Jun interactions, acid/base coiled coil structure based interactions (e.g. helices), antibody/antigen interactions, polynucleotide-polynucleotide interactions e.g. DNA/DNA, DNA/PNA, DNA/RNA, PNA/PNA, LNA/DNA; synthetic molecule-synthetic molecule interactions and protein-small molecule interactions, IgG dimeric protein, IgM multivalent protein, chelate/metal ion-bound chelate, strep immunoglobulins, antibodies (monoclonal, polyclonal, and recombinant), antibody fragments and derivatives thereof, hexa-his (metal chelate moiety), hexa-hat GST (glutathione S-transferase) glutathione affinity, Calmodulin-binding peptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose Binding Protein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to a diversity of compounds, including carbohydrates, lipids and proteins, e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) and tetranectin or Protein A or G (antibody affinity).

### Claim 135

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more scaffolds.

### Claim 136

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more carriers.

### Claim 137

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises at least one scaffold and at least one carrier.

### Claim 138

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprise one or more optionally substituted organic molecules.

### Claim 139

The panel according to any of the preceding claims, wherein the optionally substituted organic molecule comprises one or more functionalized cyclic structures, such as one or more benzene rings.

### Claim 140

The panel according to any of the preceding claims, wherein the optionally substituted organic molecule comprises a scaffold molecule comprising at least three reactive groups, or at least three sites suitable for non-covalent attachment.

### Claim 141

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more biological cells and/or cell-like structures.

### Claim 142

The panel according to any of the preceding claims, wherein the one or more biological cells are selected from the group consisting of antigen presenting cells, dendritic cells, macrophages, Kupfer cells, Langerhans cells, and B-cells.

### Claim 143

The panel according to any of the preceding claims, wherein the one or more biological cells are alive and mitotic active; are alive and mitotic inactive; or are dead.

### Claim 144

The panel according to any of the preceding claims, wherein the one or more biological cells have a natural expression of MHC (i.e. not stimulated); or wherein the one or more biological cells have to be induced/stimulated by e.g. Inf-γ to express MHC.

### Claim 145

The panel according to any of the preceding claims, wherein the one or more biological cells are MHC expressing cells, are one or more transfected cells expressing MHC or are one or more hybridoma cells expressing MHC.

### Claim 146

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more membranes.

### Claim 147

The panel according to any of the preceding claims, wherein the one or more membranes comprises liposomes or micelles.

### Claim 148

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more polymers such as one or more synthetic polymers.

### Claim 149

The panel according to any of the preceding claims, wherein the one or more polymers are selected from the group consisting of polysaccharides.

### Claim 150

The panel according to any of the preceding claims, wherein the polysaccharide comprises one or more dextran moieties.

### Claim 151

The panel according to any of the preceding claims, wherein the one or more dextran moieties are covalently attached to one or more MHC peptide complexes.

### Claim 152

The panel according to any of the preceding claims, wherein the one or more dextran moieties are non-covalently attached to one or more MHC peptide complexes.

### Claim 153

The panel according to any of the preceding claims, wherein the one or more dextran moieties are modified.

### Claim 154

The panel according to any of the preceding claims, wherein the one or more dextran moieties comprises one or more amino-dextrans, such as one or more amino-dextrans modified with divinyl sulfone.

### Claim 155

The panel according to any of the preceding claims, wherein the one or more dextran moieties comprises one or more dextrans with a molecular weight of from 1,000 to 50,000 Da, such as from 1,000 to 5,000, for example 5,000 to 10,000, such as from 10,000 to 15,000, for example 15,000 to 20,000, such as from 20,000 to 25,000, for example 25,000 to 30,000, such as from 30,000 to 35,000, for example 35,000 to 40,000, such as from 40,000 to 45,000, for example 45,000 to 50,000 Da, including any consecutive combination of the afore-mentioned ranges.

### Claim 156

The panel according to any of the preceding claims, wherein the one or more dextran moieties comprises one or more dextrans with a molecular weight of from 50,000 to 150,000 Da, such as from 50,000 to 60,000, for example 60,000 to 70,000, such as from 70,000 to 80,000, for example 80,000 to 90,000, such as from 90,000 to 100,000, for example 100,000 to 110,000, such as from 110,000 to 120,000, for example 120,000 to 130,000, such as from 130,000 to 140,000, for example 140,000 to 150,000 Da, including any consecutive combination of the afore-mentioned ranges.

### Claim 157

The panel according to any of the preceding claims, wherein the one or more dextran moieties comprises one or more dextrans with a molecular weight of from 150,000-270,00ODa such as from 150,000 to 160,000, for example 160,000 to 170,000, such as from 170,000 to 180,000, for example 180,000 to 190,000, such as from 190,000 to 200,000, for example 200,000 to 210,000, such as from 210,000 to 220,000, for example 220,000 to 230,000, such as from 230,000 to 240,000, for example 240,000 to 250,000, such as from 250,000 to 260,000, for example 260,000 to 270,000, such as from 270,000 to 280,000, for example 280,000 to 290,000, such as from 290,000 to 300,000, for example 300,000 to 310,000 such as from 310,000 to 320,000, for example 320,000 to 330,000 such as from 330,000 to 340,000, for example 340,000 to 350,000 such as from 350,000 to 360,000, for example 360,000 to 370,000 such as from 370,000 to 380,000, for example 380,000 to 390,000, such as from 390,000 to 400,000, for example 400,000 to 410,000, such as from 410,000 to 420,000, for example 420,000 to 430,000, such as from 430,000 to 440,000, for example 440,000 to 450,000, such as from 450,000 to 460,000, for example 460,000 to 470,000, such as from 470,000 to 480,000, for example 480,000 to 490,000, such as from 490,000 to 500,000, for example 500,000 to 550,000, such as from 550,000 to 600,000, for example 600,000 to 650,000, such as from 650,000 to 700,000, for example 700,000 to 750,000, such as from 750,000 to 800,000, for example 800,000 to 850,000, such as from 850,000 to 900,000, for example 900,000 to 950,000, such as from 950,000 to 1,000,000 Da, including any consecutive combination of the afore-mentioned ranges.

### Claim 158

The panel according to any of the preceding claims, wherein the one or more dextran moieties are linear.

### Claim 159

The panel according to any of the preceding claims, wherein the one or more dextran moieties are branched.

### Claim 160

The panel according to any of the preceding claims, wherein the one or more synthetic polymers are selected from the group consisting of PNA, polyamide and PEG.

### Claim 161

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more entities selected from the group consisting of an IgG domain, a coiled-coil polypeptide structure, a DNA duplex, a nucleic acid duplex, PNA-PNA, PNA-DNA and DNA-RNA.

### Claim 162

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises an antibody.

### Claim 163

The panel according to any of the preceding claims, wherein the antibody is selected from the group consisting of polyclonal antibody, monoclonal antibody, IgA, IgG, IgM, IgD, IgE, IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2, humanized antibody, humanized monoclonal antibody, chimeric antibody, mouse antibody, rat antibody, rabbit antibody, human antibody, camel antibody, sheep antibody, engineered human antibody, epitope-focused antibody, agonist antibody, antagonist antibody, neutralizing antibody, naturally-occurring antibody, isolated antibody, monovalent antibody, bispecific antibody, trispecific antibody, multispecific antibody, heteroconjugate antibody, immunoconjugates, immunoliposomes, labeled antibody, antibody fragment, domain antibody, nanobody, minibody, maxibody, diabody and fusion antibody.

### Claim 164

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more small organic scaffold molecules or small organic molecules.

### Claim 165

The panel according to any of the preceding claims, wherein the one or more small organic molecules comprises one or more steroids, one or more peptides, one or more aromatic organic molecules.

### Claim 166

The panel according to any of the preceding claims, wherein the one or more aromatic organic molecules comprises one or more one or more dicyclic structures, one or more polycyclic structures or one or more monocyclic structures.

### Claim 167

The panel according to any of the preceding claims, wherein the one or more monocyclic structures comprises one or more optionally functionalized or substituted benzene rings.

### Claim 168

The panel according to any of the preceding claims, wherein the one or more small organic molecules comprises one or more aliphatic molecules.

### Claim 169

The panel according to any of the preceding claims, wherein the one or more aliphatic molecules comprises one or more monocyclic molecules, one or more dicyclic molecules, or one or more polycyclic molecules.

### Claim 170

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more monomeric molecules able to polymerize.

### Claim 171

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more biological polymers such as one or more proteins.

### Claim 172

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more small molecule scaffolds.

### Claim 173

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more supramolecular structure(s) such as one or more nanoclusters.

### Claim 174

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more protein complexes.

### Claim 175

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises one or more beads.

### Claim 176

The panel according to any of the preceding claims, wherein the one or more beads are selected from the group consisting of beads that carry electrophilic groups e.g. divinyl sulfone activated polysaccharide, polystyrene beads that have been functionalized with tosyl-activated esters, magnetic polystyrene beads functionalized with tosyl-activated esters, and beads where MHC complexes have been covalently immobilized to these by reaction of nucleophiles comprised within the MHC complex with the electrophiles of the beads.

### Claim 177

The panel according to any of the preceding claims, wherein the one or more beads are selected from the groups consisting of sepharose beads, sephacryl beads, polystyrene beads, agarose beads, polysaccharide beads, polycarbamate beads and any other kind of beads that can be suspended in an aqueous buffer.

### Claim 178

The panel according to any of the preceding claims, wherein the multimerization domain comprises one or more compounds selected from the group consisting of agarose, sepharose, resin beads, glass beads, pore-glass beads, glass particles coated with a hydrophobic polymer, chitosan-coated beads, SH beads, latex beads spherical latex beads, allele-type beads, SPA bead, PEG-based resins, PEG-coated bead, PEG-encapsulated bead, polystyrene beads, magnetic polystyrene beads, glutathione agarose beads, magnetic bead, paramagnetic beads, protein A and/or protein G sepharose beads, activated carboxylic acid bead, macroscopic beads, microscopic beads, insoluble resin beads, silica-based resins, cellulosic resins, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins, beads with iron cores, metal beads, dynabeads, Polymethylmethacrylate beads activated with NHS, streptavidin-agarose beads, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, nitrocellulose, polyacrylamides, gabbros, magnetite, polymers, oligomers, non-repeating moieties, polyethylene glycol (PEG), monomethoxy-PEG, mono-(C1-C10)alkoxy-PEG, aryloxy-PEG, poly-(N-vinyl pyrrolidone)PEG, tresyl monomethoxy PEG, PEG propionaldehyde, bis-succinimidyl carbonate PEG, polystyrene bead crosslinked with divinylbenzene, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, dextran, aminodextran, carbohydrate-based polymers, cross-linked dextran beads, polysaccharide beads, polycarbamate beads, divinyl sulfone activated polysaccharide, polystyrene beads that have been functionalized with tosyl-activated esters, magnetic polystyrene beads functionalized with tosyl-activated esters, streptavidin beads, streptaivdin-monomer coated beads, streptaivdin-tetramer coated beads, Streptavidin Coated Compel Magnetic beads, avidin coated beads, dextramer coated beads, divinyl sulfone-activated dextran, Carboxylate-modified bead, amine-modified beads, antibody coated beads, cellulose beads, grafted co-poly beads, polyacrylamide beads, dimethylacrylamide beads optionally crosslinked with N—N′-bis-acryloylethylenediamine, hollow fiber membranes, fluorescent beads, collagen-agarose beads, gelatin beads, collagen-gelatin beads, collagen-fibronectin-gelatin beads, collagen beads, chitosan beads, collagen-chitosan beads, protein-based beads, hydrogel beads, hemicellulose, alkyl cellulose, hydroxyalkyl cellulose, carboxymethylcellulose, sulfoethylcellulose, starch, xylan, amylopectine, chondroitin, hyarulonate, heparin, guar, xanthan, mannan, galactomannan, chitin and chitosan.

### Claim 179

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a dimerization domain.

### Claim 180

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a trimerization domain.

### Claim 181

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a tetramerization domain.

### Claim 182

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a pentamerization domain.

### Claim 183

The panel according to any of the preceding claims, wherein the pentamerization domain comprises a coiled-coil polypeptide structure.

### Claim 184

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a hexamerization domain.

### Claim 185

The panel according to any of the preceding claims, wherein the hexamerization domain comprises three IgG domains.

### Claim 186

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a polymer structure to which is attached one or more scaffolds.

### Claim 187

The panel according to any of the preceding claims, wherein the polymer structure comprises a polysaccharide.

### Claim 188

The panel according to any of the preceding claims, wherein the polysaccharide comprises one or more dextran moieties.

### Claim 189

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a polyamide and/or a polyethylene glycol and/or a polysaccharide and/or a sepharose.

### Claim 190

The panel according to any of the preceding claims, wherein the one or more multimerization domains comprises a carboxy methyl dextran and/or a dextran polyaldehyde and/or a carboxymethyl dextran lactone and/or a cyclodextrin.

### Claim 191

The panel according to any of the preceding claims, wherein the one or more multimerization domains have a molecular weight of less than 1,000 Da; of from 1,000 Da to less than 10,000 Da; of from 10,000 Da to less than 100,000 Da; of from 100,000 Da to less than 1,000,000 Da; or of more than 1,000,000 Da.

### Claim 192

The panel according to any of the preceding claims wherein said one or more MHC multimers further comprising one or more scaffolds, carriers and/or linkers selected from the group consisting of streptavidin (SA) and avidin and derivatives thereof, biotin, immunoglobulins, antibodies (monoclonal, polyclonal, and recombinant), antibody fragments and derivatives thereof, leucine zipper domain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hat GST (glutathione S-tranferase) glutathione affinity, Calmodulin-binding peptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose Binding Protein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to a diversity of compounds, including carbohydrates, lipids and proteins, e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) and tetranectin or Protein A or G (antibody affinity).

### Claim 193

The panel according to any of the preceding claims, wherein said MHC multimer comprises a plurality of identical or different multimerization domains linked by a multimerization domain linking moiety.

### Claim 194

The panel according to any of the preceding claims, wherein said MHC multimer comprises a first multimerization domain linked to a second multimerization domain.

### Claim 195

The panel according to any of the preceding claims wherein said one or more MHC multimers comprises one or more covalently attached labels.

### Claim 196

The panel according to any of the preceding claims wherein said one or more MHC multimers comprises one or more non-covalently attached labels.

### Claim 197

The panel according to any of the preceding claims, wherein the one or more labels are attached to the MHC polypeptide a.

### Claim 198

The panel according to any of the preceding claims, wherein the one or more labels are attached to the MHC polypeptide b.

### Claim 199

The panel according to any of the preceding claims, wherein the one or more labels are attached to the peptide P.

### Claim 200

The panel according to any of the preceding claims, wherein the one or more labels are attached to the one or more multimerization domains.

### Claim 201

The panel according to any of the preceding claims, wherein the one or more labels are attached to (a-b-P)n.

### Claim 202

The panel according to any of the preceding claims comprising one label.

### Claim 203

The panel according to any of the preceding claims comprising more than one label, such as two or more labels, wherein said two or more labels are identical or different.

### Claim 204

The panel according to any of the preceding claims, wherein the one or more labels is attached to (a-b-P) via a streptavidin-biotin linkage.

### Claim 205

The panel according to any of the preceding claims, wherein the one or more labels is a fluorophore label.

### Claim 206

The panel according to any of the preceding claims, wherein the one or more labels is a fluorophore label selected from the group of fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine; 2-(4′-maleimidylanilino)naphthalene-6-sulfonic acid, sodium salt; 5-((((2-iodoacetyl)amino)ethyl)amino) naphthalene-1-sulfonic acid; Pyrene-1-butanoic acid; AlexaFluor 350 (7-amino-6-sulfonic acid-4-methyl coumarin-3-acetic acid; AMCA (7-amino-4-methyl coumarin-3-acetic acid); 7-hydroxy-4-methyl coumarin-3-acetic acid; Marina Blue (6,8-difluoro-7-hydroxy-4-methyl coumarin-3-acetic acid); 7-dimethylamino-coumarin-4-acetic acid; Fluorescamin-N-butyl amine adduct; 7-hydroxy-coumarine-3-carboxylic acid; CascadeBlue (pyrene-trisulphonic acid acetyl azide; Cascade Yellow; Pacific Blue (6,8 difluoro-7-hydroxy coumarin-3-carboxylic acid; 7-diethylamino-coumarin-3-carboxylic acid; N-(((4-azidobenzoyl)amino)ethyl)-4-amino-3,6-disulfo-1,8-naphthalimide, dipotassium salt; Alexa Fluor 430; 3-perylenedodecanoic acid; 8-hydroxypyrene-1,3,6-trisulfonic acid, trisodium salt; 12-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)dodecanoic acid; N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine; Oregon Green 488 (difluoro carboxy fluorescein); 5-iodoacetamidofluorescein; propidium iodide-DNA adduct; and Carboxy fluorescein.

### Claim 207

The panel according to any of the preceding claims, wherein the one or more labels is a fluorescent label, such as a simple fluorescent label.

### Claim 208

The panel according to any of the preceding claims, wherein the one or more fluorescent label is selected from the group Fluor dyes, Pacific Blue™, Pacific Orange™, Cascade Yellow™; AlexaFluor®(AF), AF405, AF488, AF500, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710, AF750, AF800; Quantum Dot based dyes, QDot® Nanocrystals (Invitrogen, MolecularProbs), Qdot®525, Qdot®565, Qdot®585, Qdot®605, Qdot®655, Qdot®705, Qdot®800; DyLight™ Dyes (Pierce) (DL); DL549, DL649, DL680, DL800; Fluorescein (Flu) or any derivate of that, such as FITC; Cy-Dyes, Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7; Fluorescent Proteins, RPE, PerCp, APC, Green fluorescent proteins; GFP and GFP derivated mutant proteins; BFP, CFP, YFP, DsRed, T1, Dimer2, mRFP1, MBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry, mCherry; Tandem dyes, RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor® tandem conjugates; RPE-Alexa610, RPE-TxRed, APC-Aleca600, APC-Alexa610, APC-Alexa750, APC-Cy5, APC-Cy5.5; multi fluorochrome assemblies, Multiple fluorochromes attached to a polymer molecule, such as a peptide/protein, Dextrane, polysaccharide, any combination of the fluorescent dyes involving in generation of FRET (Fluorescence resonance energy transfer) based techniques; ionophors; and ion chelating fluorescent props, props that change wavelength when binding a specific ion, such as Calcium, props that change intensity when binding to a specific ion, such as Calcium.

### Claim 209

The panel according to any of the preceding claims, wherein the one or more labels is capable of absorption of light, such as a chromophore and a dye.

### Claim 210

The panel according to any of the preceding claims, wherein the one or more labels is capable of emission of light after excitation, such as one or more fluorochromes.

### Claim 211

The panel according to any of the preceding claims, wherein the one or more fluorochromes is selected from the AlexaFluor®(AF) family, which include AF®350, AF405, AF430, AF488, AF500, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710, AF750 and AF800; selected from the Quantum Dot (Qdot®) based dye family, which include Qdot®525, Qdot®565, Qdot®585, Qdot®605, Qdot®655, Qdot®705, Qdot®800; selected from the DyLight™ Dyes (DL) family, which include DL549, DL649, DL680, DL800; selected from the family of Small fluorescing dyes, which include FITC, Pacific Blue™, Pacific Orange™, Cascade Yellow™, Marina Blue™, DSred, DSred-2, 7-AAD, TO-Pro-3; selected from the family of Cy-Dyes, which include Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7; selected from the family of Phycobili Proteins, which include R-Phycoerythrin (RPE), PerCP, Allophycocyanin (APC), B-Phycoerythrin, C-Phycocyanin; selected from the family of Fluorescent Proteins, which include (E)GFP and GFP ((enhanced) green fluorescent protein) derived mutant proteins; BFP, CFP, YFP, DsRed, T1, Dimer2, mRFP1, MBanana, mOrange, dTomato, tdTomato, mTangerine; selected from the family of Tandem dyes with RPE, which include RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor® tandem conjugates; RPE-Alexa610, RPE-TxRed; selected from the family of Tandem dyes with APC, which include APC-Aleca600, APC-Alexa610, APC-Alexa750, APC-Cy5, APC-Cy5.5; selected from the family of Calcium dyes, which include Indo-1-Ca2+ Indo-2-Ca2+.

### Claim 212

The panel according to any of the preceding claims, wherein the one or more labels is capable of reflection of light, such as gold, plastic, glass, polystyrene and/or pollen.

### Claim 213

The panel according to any of the preceding claims, wherein the one or more labels is a chemiluminescent label, such as a chemiluminescent label selected from the group luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

### Claim 214

The panel according to any of the preceding claims, wherein the one or more labels is a bioluminescent label, such as a bioluminescent label selected from the group luciferin, luciferase and aequorin.

### Claim 215

The panel according to any of the preceding claims, wherein the one or more labels is a radioactive label, such as a radionuclide, an isotope, comprising a rays, comprising p rays or comprising γ rays.

### Claim 216

The panel according to any of the preceding claims, wherein the one or more labels is an enzyme label.

### Claim 217

The panel according to any of the preceding claims, wherein the one or more labels is an enzyme label, wherein
the enzyme catalyze a reaction between chemicals in the near environment of the labeling molecules, producing a light signal (chemi-luminescence),
the enzyme catalyze a reaction between chemicals in the near environment of the labeling molecules, resulting in precipitation of chromophor dyes, or
the enzyme catalyze a reaction between chemicals in the near environment of the labeling molecules, resulting in precipitates that can be detected by an additional layer of detection molecules.

### Claim 218

The panel according to any of the preceding claims, wherein the one or more labels is an enzyme label selected from the group consisting of peroxidases, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.

### Claim 219

The panel according to any of the preceding claims, wherein the enzyme label is horseradish peroxidase, and optionally the substrate is selected from the group consisting of diaminobenzidine (DAB), 3-amino-9-ethyl-carbazole (AEC+), biotinyl tyramide and fluorescein tyramide.

### Claim 220

The panel according to any of the preceding claims, wherein the enzyme label is alkaline phosphatase, and optionally the substrate is Fast red dye.

### Claim 221

The panel according to any of the preceding claims wherein the one or more labels is a ionophore or chelating chemical compound binding to specific ions such as Ca2+.

### Claim 222

The panel according to any of the preceding claims, wherein the one or more labels is a lanthanide; such as a lanthanide that comprises fluorescence, a lanthanide that comprises Phosphorescence, or a paramagnetic lanthanide.

### Claim 223

The panel according to any of the preceding claims, wherein the one or more labels is a DNA fluorescing stain.

### Claim 224

The panel according to any of the preceding claims, wherein the one or more labels is a DNA fluorescing stain selected from the group consisting of Propidium iodide, Hoechst stain, DAPI, AMC, DraQ5™ and Acridine orange.

### Claim 225

The panel according to any of the preceding claims, wherein said label is a nucleic acid label.

### Claim 226

The panel according to any of the preceding claims, wherein said label is a nucleic acid label selected from the group consisting of a DNA label, an RNA label, and an artificial nucleic acid label.

### Claim 227

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising one or more nucleotides individually derived from one or more of DNA, RNA, and an artificial nucleic acid.

### Claim 228

The panel according to any of the preceding claims, wherein said artificial nucleic acid is selected from the group consisting of XNA, LNA, PNA, GNA, TNA, HNA, CeNA, and morpholino-nucleic acids.

### Claim 229

The panel according to any of the preceding claims, wherein said label is a DNA label.

### Claim 230

The panel according to any of the preceding claims, wherein said nucleic acid label comprises 1 to 1,000,000 nucleic acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleic acids; for example 1-3, 3-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-175, 175-200, 200-250, 250-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000, 2000-3000, 3000-4000, 4000-5000, 5000-7500, 7500-10,000, 10,000-100,000, 100,000-1,000,000 nucleic acids.

### Claim 231

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising one or more of
a) barcode region,
b) 5′ first primer region (forward)
c) 3′ second primer region (reverse),
d) random nucleotide region,
e) connector molecule
f) stability-increasing components
g) short nucleotide linkers in between any of the above-mentioned components
h) adaptors for sequencing
i) annealing region

### Claim 232

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising at least a barcode region.

### Claim 233

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising at least a barcode region, wherein said barcode region comprises a sequence of consecutive nucleic acids.

### Claim 234

The panel according to any of the preceding claims, wherein the barcode region of said nucleic acid comprises 1-3, 3-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-175, 175-200, 200-250, 250-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000 nucleic acids.

### Claim 235

The panel according to any of the preceding claims, wherein said barcode region comprises or consists of 5-10, 10-15, 15-20, 20-25, 25-30, 30-40, 40-45, 45-50 nucleic acids.

### Claim 236

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising at least a 3′ primer region, a barcode region, and a 5′ primer region.

### Claim 237

The panel according to any of the preceding claims, wherein said label is a nucleic acid label comprising at least a 3′ primer region, a barcode region, and a 5′ primer region, wherein said barcode region is designed to be amplified by e.g. PCR and identified by e.g. sequencing.

### Claim 238

The panel according to any of the preceding claims, wherein the primer regions of said nucleic acid label are identical for subsets of MHC multimers comprising different labels.

### Claim 239

The panel according to any of the preceding claims, wherein said nucleic acid label comprises a random nucleotide region comprising 3-20 nucleotides, such as 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14,15, 16, 17, 18, 19 or 20 nt.

### Claim 240

The panel according to any of the preceding claims, wherein said nucleic acid label comprises one or more stability-increasing components, such as HEG or TEG.

### Claim 241

The panel according to any of the preceding claims, wherein a sample identifying sequence is attached to the nucleic acid label such as by attachment to one of the primers capable of binding to the primer regions of the nucleic acid label.

### Claim 242

The panel according to any of the preceding claims, wherein said label is a peptide label.

### Claim 243

The panel according to any of the preceding claims, wherein said peptide label comprises a stretch of consecutive amino acid residues (coding region).

### Claim 244

The panel according to any of the preceding claims, wherein said peptide label comprises a stretch of consecutive amino acid residues (coding region) and a protease cleavage site.

### Claim 245

The panel according to any of the preceding claims, wherein said protease cleavage site in said peptide label is located proximal to the linker that connects the label to the MHC multimer.

### Claim 246

The panel according to any of the preceding claims, wherein said peptide label comprising a protease cleavage site that allows for cleavage of the stretch of consecutive amino acid residues (coding region) and release thereof from the MHC multimer.

### Claim 247

The panel according to any of the preceding claims, wherein said label is a peptide label comprising 2 or more consecutive amino acids, such as 2-3, 3-4, 4-5, 5-6,6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, 20-21, 21-22, 22-23, 23-24, 24-25, 25-26, 26-27, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70,70-75, 75-80, 80-85, 85-90, 90-95, 95-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170,170-180, 180-190, 190-200, 200-225, 225-250, 250-275, 275-300, 300-350, 350-400, 400-450, 450-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1500, 1500-2000, or more than 2000, consecutive amino acids.

### Claim 248

The panel according to any of the preceding claims, wherein said peptide label comprises proteinogenic and/or non-proteinogenic amino acids.

### Claim 249

The panel according to any of the preceding claims, wherein the MHC multimer comprises one or more further polypeptides in addition to a and b.

### Claim 250

The panel according to any of the preceding claims, wherein P is chemically modified.

### Claim 251

The panel according to any of the preceding claims, wherein P is pegylated, phosphorylated and/or glycosylated.

### Claim 252

The panel according to any of the preceding claims, wherein one of the amino acid residues of the peptide P is substituted with another amino acid.

### Claim 253

The panel according to any of the preceding claims, wherein a and b are both full-length peptides.

### Claim 254

The panel according to any of the preceding claims, wherein a is a full-length peptide.

### Claim 255

The panel according to any of the preceding claims, wherein b is a full-length peptide.

### Claim 256

The panel according to any of the preceding claims, wherein a is truncated.

### Claim 257

The panel according to any of the preceding claims, wherein b is truncated.

### Claim 258

The panel according to any of the preceding claims, wherein a and b are both truncated.

### Claim 259

The panel according to any of the preceding claims, wherein a is covalently linked to b.

### Claim 260

The panel according to any of the preceding claims, wherein a is covalently linked to P.

### Claim 261

The panel according to any of the preceding claims, wherein b is covalently linked to P.

### Claim 262

The panel according to any of the preceding claims, wherein a, b and P are all covalently linked.

### Claim 263

The panel according to any of the preceding claims, wherein a is non-covalently linked to b.

### Claim 264

The panel according to any of the preceding claims, wherein a is non-covalently linked to P.

### Claim 265

The panel according to any of the preceding claims, wherein b is non-covalently linked to P.

### Claim 266

The panel according to any of the preceding claims, wherein a, b and P are all non-covalently linked.

### Claim 267

The panel according to any of the preceding claims, wherein a is not included in the (a-b-P) complex.

### Claim 268

The panel according to any of the preceding claims, wherein b is not included in the (a-b-P) complex.

### Claim 269

The panel according to any of the preceding claims, wherein P is not included in the (a-b-P) complex.

### Claim 270

The panel according to any of the preceding claims, wherein one of the polypeptides of the MHC-peptide complex is a P2M polypeptide.

### Claim 271

The panel according to any of the preceding claims, wherein one of the polypeptides of the MHC-peptide complex is a heavy chain polypeptide.

### Claim 272

A method for generating the MHC multimers according to any of the preceding claims, said method comprising the steps of
i) providing one or more antigenic peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42;
ii) providing one or more functional MHC proteins,
iii) providing one or more multimerization domains, and
iv) contacting or reacting the one or more peptides P and the one or more functional MHC proteins and the one or more multimerization domains simultaneously or sequentially in any order, thereby obtaining said MHC multimers.

### Claim 273 (depends on 272)

The method of claim 272 comprising the steps of
i) providing one or more antigenic peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42;
ii) providing one or more functional MHC proteins (a-b) capable of binding peptide P, wherein each functional MHC protein is associated with one or more multimerization domains; and
iii) contacting or reacting the one or more peptides P and the one or more functional MHC proteins associated with one or more multimerization domains thereby obtaining said MHC multimers.

### Claim 274 (depends on 272)

The method of claim 272 comprising the steps of
i) providing one or more MHC-peptide complexes (a-b-P) comprising a functional MHC protein (a-b) bound to peptide P, wherein each MHC-peptide complex comprises an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42;
ii) providing one or more multimerization domains, and
iii) contacting or reacting the one or more MHC-peptide complexes and the one or more multimerization domains thereby obtaining said MHC multimers.

### Claim 275

The method of any of the preceding claims, wherein said one or more multimerization domains is defined in any of the preceding claims.

### Claim 276

The method of any of the preceding claims, wherein said one or more multimerization domains comprises one or more biological cells and/or cell-like structures, membranes, liposomes and/or micelles.

### Claim 277

The method of any of the preceding claims, wherein said one or more multimerization domains comprises one or more biological cells which are:
i) selected from the group consisting of antigen presenting cells, dendritic cells, macrophages, Kupfer cells, Langerhans cells and B-cells,
ii) alive and mitotic active; are alive and mitotic inactive; or are dead
iii) a natural expression of MHC; or have to be induced/stimulated to express MHC.
iv) are MHC expressing cells, are one or more transfected cells expressing MHC or are one or more hybridoma cells expressing MHC.

### Claim 278

The method of any of the preceding claims, wherein each of said one or more antigenic peptides P are selected from the group consisting of 8-, 9-, 10,- 11-, and 12-mer peptides that binds to MHC Class I.

### Claim 279

The method of any of the preceding claims, wherein each of said one or more antigenic peptides P are derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37), and P37-42 (SEQ ID NOs:38-39).

### Claim 280

The method of any of the preceding claims, wherein each of said one or more antigenic peptides P are selected from the group consisting of
i) antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20),
ii) antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19),
iii) antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20),
iv) antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and/or
v) antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20).

### Claim 281

The method of any of the preceding claims, wherein said reaction(s) involves a covalent coupling of the MHC-peptide complex and the multimerization domain(s) comprising nucleophilic substitution by activation of electrophiles, preferably acylation, such as amide formation, pyrazolone formation, isoxazolone formation; alkylation; vinylation; and disulfide formation.

### Claim 282

The method of any of the preceding claims, wherein said reaction(s) involves a covalent coupling of the MHC-peptide complex and the multimerization domain(s) comprising addition to carbon-hetero multiple bonds, preferably by alkene formation by reaction of phosphonates with aldehydes or ketones; or arylation; alkylation of arenes/hetarenes by reaction with alkyl boronates or enolethers.

### Claim 283

The method of any of the preceding claims, wherein said reaction(s) involves a covalent coupling of the MHC-peptide complex and the multimerization domain comprising nucleophilic substitution using activation of nucleophiles, preferably by condensations; alkylation of aliphatic halides or tosylates with enolethers or enamines.

### Claim 284

The method of any of the preceding claims, wherein said reaction involves a covalent coupling of the MHC-peptide complex and the multimerization domain comprises cycloadditions.

### Claim 285

The method of any of the preceding claims, wherein the one or more MHC peptide complexes comprises MHC class I heavy chain and/or beta2-Microglobulin.

### Claim 286

The method of any of the preceding claims, wherein the MHC class I heavy chain and/or beta2-Microglobulin is derived from natural sources.

### Claim 287

The method of any of the preceding claims, wherein the MHC class I heavy chain and/or beta2-Microglobulin is generated by recombinant means.

### Claim 288

The method of any of the preceding claims, wherein the recombinant means comprises in vitro translation of mRNA obtained from expressing cells.

### Claim 289

The method of any of the preceding claims, wherein the recombinant means comprises use of beta2-microglubulin and/or MHC class I Heavy chain transfected cells.

### Claim 290

The method of any of the preceding claims, wherein the use of beta-2-microglubulin and/or MHC class I Heavy chain transfected cells comprises use of genetic material isolated from natural origin such as cells, one or more tissues and/or one or more organisms.

### Claim 291 (depends on 807)

The method of claim 807, wherein the use of beta-2-microglubulin and/or MHC class I Heavy chain transfected cells comprises use of one or more synthetic genes identical to natural DNA sequence and/or modified.

### Claim 292

The method of any of the preceding claims, wherein the beta-2-microglubulin is full length.

### Claim 293

The method of any of the preceding claims, wherein the beta-2-microglubulin is a fragment.

### Claim 294

The method of any of the preceding claims, wherein the MHC class I Heavy chain is full length.

### Claim 295

The method of any of the preceding claims, wherein the MHC class I Heavy chain is a fragment.

### Claim 296

The method of any of the preceding claims, wherein the MHC class I Heavy chain fragment comprises and/or consists of the complete chain minus the intramembrane domain.

### Claim 297

The method of any of the preceding claims, wherein the MHC class I Heavy chain fragment comprises and/or consists of the alpha1 and alpha 2 class 1 heavy chain domains.

### Claim 298

The method of any of the preceding claims, wherein the beta2-microglubulin and/or MHC class I Heavy chain fragment comprises one or more added designer domain(s) and/or sequences(s).

### Claim 299

The method of any of the preceding claims, wherein the MHC class I heavy chain and/or beta2-Microglobulin is generated by chemical synthesis.

### Claim 300

The method of any of the preceding claims, wherein the chemical synthesis comprises solid phase synthesis.

### Claim 301

The method of any of the preceding claims, wherein the one or more MHC peptide complexes are modified.

### Claim 302

The method of any of the preceding claims, wherein the one or more MHC peptide complexes that are modified are one or more MHC class I complexes.

### Claim 303

The method of any of the preceding claims, wherein the one or more MHC class I complexes are modified by mutagenesis.

### Claim 304

The method of any of the preceding claims, wherein the mutagenesis comprises one or more substitutions of one or more natural and/or non-natural amino acids.

### Claim 305

The method of any of the preceding claims, wherein the mutagenesis comprises one or more deletions of one or more natural and/or non-natural amino acids.

### Claim 306

The method of any of the preceding claims, wherein the mutagenesis comprises one or more insertions of one or more natural and/or non-natural amino acids.

### Claim 307

The method of any of the preceding claims, wherein the mutagenesis comprises one or more mutations in the α3 subunit of MHC I heavy chain.

### Claim 308

The method of any of the preceding claims, wherein the one or more chemical modification(s) comprises one or more chemical modification(s) of the peptide in the peptide-binding cleft such as attachment of a dinitrophenyl group.

### Claim 309

The method of any of the preceding claims, wherein the one or more chemical modification(s) comprises one or more chemical modification(s) of MHC I fusion proteins.

### Claim 310

The method of any of the preceding claims, wherein the one or more chemical modification(s) comprises one or more chemical modification(s) of MHC complexes fused with genes encoding an amino acid sequence (biotinylation sequence) capable of being biotinylated with a Bir A enzyme.

### Claim 311

The method of any of the preceding claims, wherein the biotinylation sequence is fused with the COOH-terminal of β2m or the heavy chain of MHC I molecules.

### Claim 312

The method of any of the preceding claims, wherein the biotinylation sequence is fused with the NH2-terminal of β2m or the heavy chain of MHC I molecules.

### Claim 313

The method of any of the preceding claims, wherein the one or more chemical modification(s) comprises one or more chemical modification(s) of MHC complexes fused with genes encoding an amino acid sequence capable of being chemically modified.

### Claim 314

The method of any of the preceding claims, wherein the one or more genes encoding an amino acid sequence capable of being chemically modified are fused with the COOH-terminal of β2m or the heavy chain of MHC I molecules.

### Claim 315

The method of any of the preceding claims, wherein the one or more genes encoding an amino acid sequence capable of being chemically modified are fused with the NH2-terminal of β2m or the heavy chain of MHC I molecules.

### Claim 316

The method of any of the preceding claims, wherein the one or more MHC peptide complexes and/or empty MHC complexes are stabilized.

### Claim 317

The method of any of the preceding claims, wherein the one or more MHC peptide complexes and/or empty MHC complexes that are stabilized are one or more MHC class I complexes.

### Claim 318

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises generation of covalent protein-fusions.

### Claim 319

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers between the individual components of the MHC I complex.

### Claim 320

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers resulting in generation of a complex comprising a heavy chain fused with β2m through a linker and a soluble peptide.

### Claim 321

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers resulting in generation of a complex comprising a heavy chain fused to β2m through a linker.

### Claim 322

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers resulting in generation of a complex comprising a heavy chain/β2m dimer covalently linked to a peptide through a linker to either heavy chain or β2m, and where there can or can not be a linker between the heavy chain and β2m.

### Claim 323

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers resulting in generation of a complex comprising a heavy chain fused to a peptide through a linker.

### Claim 324

The method of any of the preceding claims, wherein the generation of covalent protein-fusions comprises introduction of one or more linkers resulting in generation of a complex comprising the α1 and α2 subunits of the heavy chain fused to a peptide through a linker.

### Claim 325

The method of any of the preceding claims, wherein the heavy chain, beta2-microglubulin and/or the peptide is truncated.

### Claim 326

The method of any of the preceding claims, wherein the linker is a flexible linker.

### Claim 327

The method of any of the preceding claims, wherein the flexible linker is made of glycine and/or serine.

### Claim 328

The method of any of the preceding claims, wherein the flexible linker is between 5-20 residues long such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 residues long.

### Claim 329

The method of any of the preceding claims, wherein the linker is rigid with a defined structure.

### Claim 330

The method of any of the preceding claims, wherein the rigid linker is made of amino acids like glutamate, alanine, lysine, and leucine creating e.g. a more rigid structure.

### Claim 331

The method of any of the preceding claims, wherein the rigid linker is between 5-20 residues long such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 residues long.

### Claim 332

The method of any of the preceding claims, wherein the one or more stabilized MHC peptide complexes and/or empty MHC complexes comprises heavy chain-β2m fusion proteins.

### Claim 333

The method of any of the preceding claims, wherein the heavy chain-β2m fusion proteins is constructed so that the COOH terminus of β2m is covalently linked to the NH2 terminus of the heavy chain.

### Claim 334

The method of any of the preceding claims, wherein the heavy chain-β2m fusion proteins is constructed so that the NH2 terminus of β2m is linked to the COOH terminus of the heavy chain.

### Claim 335

The method of any of the preceding claims, wherein the one or more stabilized MHC peptide complexes and/or empty MHC complexes comprises one or more peptide-β2m fusion proteins.

### Claim 336

The method of any of the preceding claims, wherein one or more peptide-β2m fusion proteins are constructed so that the COOH terminus of the peptide is linked to the NH2 terminus of β2m.

### Claim 337

The method of any of the preceding claims, wherein one or more peptide-β2m fusion proteins are constructed so that the peptide is linked to the COOH terminal of β2m via its NH2 terminus.

### Claim 338

The method of any of the preceding claims, wherein the one or more stabilized MHC peptide complexes and/or empty MHC complexes comprises one or more heavy chain-peptide fusion proteins.

### Claim 339

The method of any of the preceding claims, wherein the one or more heavy chain-peptide fusion proteins are constructed so that the NH2 terminus of the heavy chain is fused to the COOH terminus of the peptide.

### Claim 340

The method of any of the preceding claims, wherein the one or more heavy chain-peptide fusion proteins are constructed so that the COOH terminus of the heavy chain is fused to the NH2 terminus of the peptide.

### Claim 341

The method of any of the preceding claims, wherein the one or more stabilized MHC peptide complexes and/or empty MHC complexes comprises one or more heavy chain-β2m-peptide fusion proteins.

### Claim 342

The method of any of the preceding claims, wherein the one or more heavy chain-β2m-peptide fusion proteins is constructed so that the NH2 terminus of the heavy chain is fused to the COOH terminus of β2m and the NH2 terminus of β2m is fused to the COOH terminus of the peptide.

### Claim 343

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises non-covalent stabilization by binding to one or more unnatural component.

### Claim 344

The method of any of the preceding claims, wherein the one or more unnatural component bind to both the heavy chain and the β2m and thereby promote the assemble of the complex, and/or stabilize the formed complex.

### Claim 345

The method of any of the preceding claims, wherein the one or more unnatural component bind to either β2m or heavy chain, and in this way stabilize the polypeptide in its correct conformation, and in this way increase the affinity of the heavy chain for β2m and/or peptide, or increase the affinity of β2m for peptide.

### Claim 346

The method of any of the preceding claims, wherein the one or more unnatural component comprises one or more antibodies.

### Claim 347

The method of any of the preceding claims, wherein the one or more antibodies can be selected from the group consisting of truncated or full-length antibodies of isotype IgG, IgM, IgA, IgE, Fab, scFv or bi-Fab fragments or diabodies.

### Claim 348

The method of any of the preceding claims, wherein the one or more antibodies comprises one or more antibodies binding the MHC I molecule by interaction with the heavy chain as well as β2m.

### Claim 349

The method of any of the preceding claims, wherein the one or more antibodies comprises one or more bispecific antibodies that binds with one arm to the heavy chain and the other arm to the β2m of the MHC complex.

### Claim 350

The method of any of the preceding claims, wherein the one or more antibodies comprises one or more monospecific antibodies which bind at the interface between heavy chain and β2m.

### Claim 351

The method of any of the preceding claims, wherein the one or more antibodies comprises one or more antibodies that bind the correctly folded heavy chain with higher affinity than non-correctly folded heavy chain.

### Claim 352

The method of any of the preceding claims, wherein the one or more antibodies comprises an antibody like the one produced by the clone W6/32 (M0736 from Dako, Denmark) that recognizes a conformational epitope on intact human and some monkey MHC complexes containing β2m, heavy chain and peptide.

### Claim 353

The method of any of the preceding claims, wherein the one or more unnatural component comprises one or more peptides.

### Claim 354

The method of any of the preceding claims, wherein the one or more unnatural component comprises one or more aptamers.

### Claim 355

The method of any of the preceding claims, wherein the one or more unnatural component comprises one or more molecule with the ability to bind to the surface of the MHC complex.

### Claim 356

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises generation of modified proteins or protein components.

### Claim 357

The method of any of the preceding claims, wherein the generation of modified proteins or protein components results in an increase of the affinity of the peptide P for the MHC complex.

### Claim 358

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by mutation/substitution of amino acids at relevant positions in the peptide.

### Claim 359

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by chemical modifications of amino acids at relevant positions in the peptide.

### Claim 360

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by introduction of non-natural amino acids at relevant positions in the peptide.

### Claim 361

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by mutations, chemical modifications, insertion of natural or non-natural amino acids or deletions in the peptide binding cleft, i.e. in the binding pockets that accommodate peptide side chains responsible for anchoring the peptide to the peptide binding cleft.

### Claim 362

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by introduction of reactive groups into the antigenic peptide; before, during or upon binding of the peptide.

### Claim 363

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by mutations/substitutions, chemical modifications, insertion of natural or non-natural amino acids or deletions in the heavy chain and/or β2m at positions outside the peptide-binding cleft.

### Claim 364

The method of any of the preceding claims, wherein the increase of the affinity of the peptide P for the MHC complex is caused by removal of cysteine residues in the heavy chain by mutation, chemical modification, amino acid exchange or deletion.

### Claim 365

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises stabilization with soluble additives.

### Claim 366

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition of one or more additives selected from the group consisting of salts, detergents organic solvent and polymers.

### Claim 367

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition one or more additives that increase surface tension of the MHC molecule without binding the molecule.

### Claim 368

The method of any of the preceding claims, wherein the one or more additives that increase surface tension of the MHC molecule without binding the molecule can be selected from the group consisting of sucrose, mannose, glycine, betaine, alanine, glutamine, glutamic acid and ammonium sulfate.

### Claim 369

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition one or more additives that increase surface tension of the MHC molecule.

### Claim 370

The method of any of the preceding claims, wherein the one or more additives that increase surface tension of the MHC molecule can be selected from the group consisting of glycerol, mannitol and sorbitol.

### Claim 371

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition one or more additives that increase surface tension of the MHC molecule and simultaneously interact with charged groups in the protein.

### Claim 372

The method of any of the preceding claims, wherein the one or more additives that increase surface tension of the MHC molecule and simultaneously interact with charged groups in the protein can be selected from the group consisting of MgSO4, NaCl, polyethylenglycol, 2-methyl-2,4-pentandiol and guanidiniumsulfate.

### Claim 373

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition of molar excess of peptide.

### Claim 374

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition of excess of β2m.

### Claim 375

The method of any of the preceding claims, wherein the stabilization with soluble additives comprises addition BSA, fetal and bovine calf serum and/or individual protein components in serum with a protein stabilizing effect.

### Claim 376

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises stabilization with soluble additives, said additives are added during the refolding process.

### Claim 377

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises stabilization with soluble additives, said additives are added to the soluble monomer.

### Claim 378

The method of any of the preceding claims, wherein the stabilization of one or more MHC class I complexes comprises stabilization with soluble additives, said additives are added to a solutions containing MHC I bound to a carrier.

### Claim 379 (depends on 272, 378)

The method of any of claims 272-378, said method comprising the further step of confirming the antigenicity of an antigenic peptide P and/or determining the sequence of an antigenic peptide P, said method comprising the steps of
i) selecting one or more MHC Class I alleles;
ii) obtaining and optionally identifying one or more peptides P of a predetermined length derived from a specific protein, and
iii) assaying the association formed between a) said one or more peptides P, when forming part of a functional MHC protein in a MHC multimer, and b) a T-cell receptor representative of the selected MHC Class I allele, and
iv) optionally modifying said one or more peptides P.

### Claim 380

The method of any of the preceding claims, wherein identification of the one or more peptides P derived from a specific protein for a given MHC allele comprises computational analysis using prediction software.

### Claim 381

The method of any of the preceding claims, wherein identification of the one or more peptides P derived from a specific protein for a given MHC allele comprises computational analysis of the prediction of theoretical binding affinity of the peptide P to the MHC (HLA) molecules using prediction software.

### Claim 382

The method of any of the preceding claims, wherein identification of the one or more peptides P derived from a specific protein for a given MHC allele comprises computational analysis of the prediction of a rank score relative binding strength of the peptide P to the one or more MHC Class I alleles with a relative binding strength threshold (% Rank).

### Claim 383

The method of any of the preceding claims, wherein the computational analysis comprises prediction of MHC Class I binding peptides P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 384

The method of any of the preceding claims, wherein the modification of the one or more antigenic peptides P comprises the use of one or more peptides homologous to the predicted peptide sequences; said peptides homologous having an amino acid sequence identity greater than e.g. more than 90%, more than 80% or more than 70%.

### Claim 385

The method of any of the preceding claims, wherein the one or more homologous peptide sequences arise from the existence of multiple strongly homologous alleles; arise from one or more insertions, arise from one or more deletions, arise from one or more inversions, or arise from one or more substitutions.

### Claim 386

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises the use of one or more peptides with one or more un-common amino acids such as selenocysteine and/or pyrrolysine.

### Claim 387

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises the use of one or more peptides with one or more artificial amino acids such as the isomeric D-form.

### Claim 388

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises the use of one or more peptides with one or more chemically modified amino acids.

### Claim 389

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises the use of one or more split- or combinatorial epitope origin i.e. formed by linkage of peptide fragments derived from two different peptide fragments and/or proteins.

### Claim 390

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises one or more modifications at any position of the one or more peptides e.g. at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and/or 18.

### Claim 391

The method of any of the preceding claims, wherein the modification of the one or more peptides P comprises one or more post translational modifications.

### Claim 392

The method of any of the preceding claims, wherein the one or more post translational modifications comprises acylation, alkylation, methylation. demethylation, amidation at C-terminus, biotinylation, formylation, gamma-carboxylation, glutamylation, glycosylation, glycation, glycylation, covalent attachment of one or more heme moieties, hydroxylation, iodination, isoprenylation, lipoylation, prenylation, GPI anchor formation, myristoylation, farnesylation. geranylation covalent attachment of nucleotides or derivatives thereof, ADP-ribosylation, flavin attachment, oxidation, pegylation, addition of poly-ethylen-glycol groups to a protein; modification of one or more reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine, tyrosine; covalent attachment of phosphatidylinositol; phosphopantetheinylation, phosphorylation, pyroglutamate formation, racemization of proline by prolyl isomerase, tRNA-mediated addition of amino acids such as arginylation, sulfation, selenoylation (co-translational incorporation of selenium in selenoproteins), ISGylation, SUMOylation, ubiquitination; citrullination, or deimination the conversion of arginine to citrulline; deamidation, the conversion of glutamine to glutamic acid or asparagine to aspartic acid.

### Claim 393

The method of any of the preceding claims, wherein the one or more post translational modifications comprises modifications of a single amino acid or comprises modifications of more than one amino acid i.e. in combination.

### Claim 394

The method of any of the preceding claims, wherein the one or more antigenic peptides P are obtained by digestion and/or proteolysis of a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 395

The method of any of the preceding claims, wherein the sequence of the one or more antigenic peptides is determined by elution of peptides from the MHC binding groove of a naturally existing MHC complex.

### Claim 396

The method of any of the preceding claims, wherein the one or more antigenic peptides are derived from one or more recombinant sources, such as one or more MHC class 1 peptides P.

### Claim 397

The method of any of the preceding claims, wherein the one or more antigenic peptides P are obtained from chemical synthesis.

### Claim 398

The method of any of the preceding claims, wherein the chemical synthesis comprises solid phase synthesis or fluid phase synthesis.

### Claim 399

The method of any of the preceding claims, wherein the chemical synthesis method comprises the further step of loading of the peptide into the functional MHC protein.

### Claim 400

The method of any of the preceding claims, further comprising a step to verify correct folding of the one or more MHC-peptide complexes.

### Claim 401

A composition comprising a panel comprising one or more MHC multimers according to any of the preceding claims.

### Claim 402

A composition comprising a panel comprising one or more pools of MHC multimers according to any of the preceding claims.

### Claim 403

A composition comprising a plurality of MHC multimers according to any of the preceding claims.

### Claim 404

A vaccine comprising a panel comprising one or more MHC multimers according to any of the preceding claims.

### Claim 405

A vaccine comprising a panel comprising one or more pools of MHC multimers according to any of the preceding claims

### Claim 406

The vaccine according to any of the preceding claims further comprising one or more cells, wherein the one or more cells are selected from the group consisting of: cells expressing MHC molecules and cells expressing MHC molecules that have been loaded with said one or more antigenic peptides P.

### Claim 407 (depends on 404, 405, 406)

A method for performing a vaccination of an individual in need thereof, said method comprising the steps
i) providing a vaccine according to any of the claims 404-406, and
ii) administering said vaccine to said individual and obtaining a protective immune response and thereby performing a vaccination of the said individual.

### Claim 408

A method for immune monitoring a Borrelia disease comprising one or more steps of:
i) providing a panel comprising one or more MHC multimers or a panel comprising one or more pools of MHC multimers wherein each pool comprises one or more MHC multimers, according to any of the preceding claims,
ii) providing a sample comprising a population of T cells, and
iii) measuring the presence, frequency, number, activity and/or state of T cells specific for said panel comprising MHC multimers, thereby immune monitoring said Borrelia disease.

### Claim 409

A method for diagnosing a Borrelia disease comprising one or more steps of:
i) providing a panel comprising one or more MHC multimers or a panel comprising one or more pools of MHC multimers wherein each pool comprises one or more MHC multimers, according to any of the preceding claims,
ii) providing a sample comprising a population of T cells, and
iii) measuring the presence, frequency, number, activity and/or state of T cells specific for said panel comprising MHC multimers, thereby diagnosing said Borrelia disease.

### Claim 410 (depends on 408, 409)

The methods according to any of claims 408-409, said methods further comprising one or more steps of treating said Borrelia disease.

### Claim 411

The methods according to any of the preceding claims, said methods further comprising one or more steps of treating said Borrelia disease by administering one or more antibiotics.

### Claim 412

The methods according to any of the preceding claims, said methods further comprising one or more steps of treating said Borrelia disease by administering one or more antibiotics selected from the group consisting of doxycycline, amoxicillin, cefuroxime axetil, azithromycin, ceftriaxone, and cefotaxime.

### Claim 413

The methods according to any of the preceding claims, wherein said Borrelia disease is a Borrelia infection.

### Claim 414

The methods according to any one of the preceding claims, wherein said Borrelia disease is a Borrelia infection caused by a borrelia species.

### Claim 415

The methods according to any one of the preceding claims, wherein said Borrelia disease is selected from the group consisting of Lyme disease (Lyme borreliosis), Erythema migrans (EM), Borrelial lymphocytoma, Lyme neuroborreliosis (LB), Carditis, Lyme Arthritis (LA), Acrodermatitis chronica atrophicans (ACA).

### Claim 416

A method for isolation of one or more antigen-specific T cells, said method comprising one or more steps of
i) providing a sample comprising a population of T cells,
ii) providing a panel comprising one or more MHC multimers, or a panel comprising one or more pools of MHC multimers wherein each pool comprises one or more MHC multimers, according to any of the preceding claims,
iii) contacting said panel with said sample comprising a population of T cells, and
iv) isolating T cells specific for said panel comprising MHC multimers.

### Claim 417

A method for detecting an antigen-specific T cell response comprising one or more steps of:
i) providing a sample comprising a population of T cells,
ii) providing a panel comprising one or more MHC multimers, or a panel comprising one or more pools of MHC multimers wherein each pool comprises one or more MHC multimers, according to any of the preceding claims,
iii) contacting said panel with said sample, and
iv) measuring the presence, frequency, number, activity and/or state of T cells specific for said panel comprising MHC multimers, thereby detecting said antigen-specific T cell response.

### Claim 418

A method for detecting an antigen-specific T cell response comprising one or more steps of:
i) providing a sample comprising a population of T cells and a population of MHC expressing cells,
ii) providing a panel comprising one or more antigenic peptides P each derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42, or
a panel comprising one or more pools of antigenic peptides P wherein each pool comprises one or more antigenic peptides P each derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42,
iii) contacting said sample with said panel, thereby allowing said antigenic peptides P and said MHC expressing cells to interact to provide MHC multimers, and
iv) measuring the presence, frequency, number, activity and/or state of T cells specific for said panel comprising antigenic peptides P, thereby detecting said antigen-specific T cell response.

### Claim 419 (depends on 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418)

The methods according to any of claims 408-418, wherein said sample comprising a population of T cells is a sample comprising T cells, monocytes and/or B cells.

### Claim 420

The methods according to any of the preceding claims, wherein said sample comprising a population of T cells is selected from a blood sample, a whole blood sample and a PBMC sample.

### Claim 421

The methods according to any of the preceding claims, wherein said sample comprising a population of MHC expressing cells comprises one or more of antigen presenting cells, dendritic cells, macrophages, Kupfer cells, Langerhans cells, monocytes and B-cells.

### Claim 422

The methods according to any of the preceding claims, wherein said sample comprising a population of MHC expressing cells comprise cells with a natural expression of MHC (i.e. not stimulated); and/or cells that needs to be induced/stimulated by e.g. Inf-γ to express MHC.

### Claim 423

The methods according to any of the preceding claims, wherein said sample comprising a population of MHC expressing cells comprise transfected cells expressing MHC and hybridoma cells expressing MHC.

### Claim 424

The methods according to any of the preceding claims, wherein said antigen-specific T cells are specific to a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 425 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424)

The method according to any of claims 416-424, wherein in step ii) said panel comprises one or more antigenic peptides P each derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37), and P37-42 (SEQ ID NOs:38-39).

### Claim 426 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425)

The method according to any of claims 416-425, wherein in step ii) said panel comprises 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10, for example 11, such as 12, for example 13, such as 14, for example 15, such as 16, for example 17, such as 18, for example 19, such as 20 antigenic peptides P each derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42,
such as an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37), and P37-42 (SEQ ID NOs:38-39).

### Claim 427 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426)

The method according to any one of claims 416-426, wherein in step ii) said panel comprises
i) one or more antigenic peptides P, such as 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 antigenic peptides P each derived from Borrelia antigenic polypeptide OppA,
ii) one or more antigenic peptides P, such as 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 antigenic peptides P each derived from Borrelia antigenic polypeptide DbpA,
iii) one or more antigenic peptides P, such as 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 antigenic peptides P each derived from Borrelia antigenic polypeptide FlhF,
iv) one or more antigenic peptides P, such as 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 antigenic peptides P each derived from Borrelia antigenic polypeptide FlaB, and/or
v) one or more antigenic peptides P, such as 1 antigenic peptide P, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10 antigenic peptides P each derived from Borrelia antigenic polypeptide P37-42.

### Claim 428 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427)

The method according to any one of claims 416-427, wherein in step ii) said panel comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA and DbpA; OppA and FlhF; OppA and FlaB; OppA and P37-42; DbpA and FlhF; DbpA and FlaB; DbpA and P37-42; FlhF and FlaB; FlhF and P37-42; or FlaB and P37-42.

### Claim 429 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428)

The method according to any one of claims 416-428, wherein in step ii) said panel comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA, DbpA and FlhF; OppA, DbpA and FlaB; OppA, DbpA and P37-42; OppA, FlhF and FlaB; OppA, FlhF and P37-42; OppA, FlaB and P37-42; DbpA, FlhF and FlaB; DbpA, FlhF and P37-42; or FlhF, FlaB and P37-42.

### Claim 430 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429)

The method according to any one of claims 416-429, wherein in step ii) said panel comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA, DbpA, FlhF and FlaB; OppA, DbpA, FlhF, P37-42; OppA, FlhF, FlaB and P37-42; OppA, DbpA, FlaB and P37-42; OppA, DbpA, FlhF and P37-42; DbpA, FlhF, FlaB and P37-42; or OppA, DbpA, FlhF, FlaB and P37-42

### Claim 431 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430)

The method according to any one of claims 416-430, wherein in step ii) said panel comprises one or more antigenic peptides P each selected from the group consisting of:
antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20),
antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19),
antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20),
antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and/or
antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20).

### Claim 432 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431)

The method according to any one of claims 416-431, wherein in step ii) said panel comprises one or more antigenic peptides P selected from the group consisting of YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEFI (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127), SQGGVNSPV (SEQ ID NO: 5112), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) or KLAESIYKRL (SEQ ID NO: 5531).

### Claim 433 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432)

The method according to any one of claims 416-432, wherein in step ii) said panel consist of antigenic peptide YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEFI (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127), SQGGVNSPV (SEQ ID NO: 5112), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) or KLAESIYKRL (SEQ ID NO: 5531).

### Claim 434 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433)

The method according to any one of claims 416-433, wherein in step ii) each pool comprises one or more antigenic peptides P each derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA (SEQ ID NOs:1-9), DbpA (SEQ ID NOs:10-20), FlhF (SEQ ID NOs:21-28), FlaB (SEQ ID NOs:29-37), and/or P37-42 (SEQ ID NOs:38-39).

### Claim 435 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434)

The method according to any one of claims 416-434, wherein in step ii) said panel comprises one or more pools of antigenic peptides P, wherein each pool comprises two or more antigenic peptides P, or
wherein in step ii) said panel comprises two or more pools of antigenic peptides P, wherein each pool comprises one or more antigenic peptides P, or
wherein in step ii) said panel comprises two or more pools of antigenic peptides P, wherein each pool comprises two or more antigenic peptides P;
wherein each antigenic peptide P is derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 436 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435)

The method according to any one of claims 416-435, wherein in step ii) said panel comprises one or more pools of antigenic peptides P, such as 1 pool, for example 2 pools, such as 3 pools, for example 4 pools, such as 5 pools, for example 6 pools, such as 7 pools, for example 8 pools, such as 9 pools, for example 10 pools of antigenic peptides P,
wherein each pool comprises one or more antigenic peptides P, such as 1 antigenic peptide P, for example 2, such as 3, for example 4, such as 5, for example 6, such as 7, for example 8, such as 9, for example 10, for example 11, such as 12, for example 13, such as 14, for example 15, such as 16, for example 17, such as 18, for example 19, such as 20 antigenic peptides P.

### Claim 437 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436)

The method according to any one of claims 416-436, wherein in step ii) one or more pools comprises one or more antigenic peptides P each selected from the group consisting of:
i) antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20),
ii) antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19),
iii) antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20),
iv) antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and/or
v) antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20).

### Claim 438 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437)

The method according to any one of claims 416-437, wherein in step ii) one or more pools comprises one or more antigenic peptides P each selected from the group consisting of:
i) antigenic peptides P derived from Borrelia antigenic polypeptide OppA (SEQ ID NOs:1-9) listed in Table A (Table A-1 to Table A-20), and including at least one or both of YLNTKSNGNYEI (SEQ ID NO: 359) and FLSIFTQGYT (SEQ ID NO: 241);
ii) antigenic peptides P derived from Borrelia antigenic polypeptide DbpA (SEQ ID NOs:10-20) listed in Table B (Table B-1 to Table B-19), and including at least GIYDLILNA (SEQ ID NO: 2761);
iii) antigenic peptides P derived from Borrelia antigenic polypeptide FlhF (SEQ ID NOs:21-28) listed in Table C (Table C-1 to Table C-20), and including at least YIKDINEFI (SEQ ID NO: 4479);
iv) antigenic peptides P derived from Borrelia antigenic polypeptide FlaB (SEQ ID NOs:29-37) listed in Table D (Table D-1 to Table D-20), and including at least one or more of IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112); and/or
v) antigenic peptides P derived from Borrelia antigenic polypeptide P37-42 (SEQ ID NOS:38-39) listed in Table E (Table E-1 to Table E-20) and including at least one or more of MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 439 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438)

The method according to any one of claims 416-438, wherein in step ii) one or more pools comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA and DbpA; OppA and FlhF; OppA and FlaB; OppA and P37-42; DbpA and FlhF; DbpA and FlaB; DbpA and P37-42; FlhF and FlaB; FlhF and P37-42; or FlaB and P37-42.

### Claim 440 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439)

The method according to any one of claims 416-439, wherein in step ii) one or more pools comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA, DbpA and FlhF; OppA, DbpA and FlaB; OppA, DbpA and P37-42; OppA, FlhF and FlaB; OppA, FlhF and P37-42; OppA, FlaB and P37-42; DbpA, FlhF and FlaB; DbpA, FlhF and P37-42; or FlhF, FlaB and P37-42.

### Claim 441 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438)

The method according to any one of claims 416-438, wherein in step ii) one or more pools comprises one or more antigenic peptides P each derived from Borrelia antigenic polypeptides: OppA, DbpA, FlhF and FlaB; OppA, DbpA, FlhF, P37-42; OppA, FlhF, FlaB and P37-42; OppA, DbpA, FlaB and P37-42; OppA, DbpA, FlhF and P37-42; DbpA, FlhF, FlaB and P37-42; or OppA, DbpA, FlhF, FlaB and P37-42.

### Claim 442 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441)

The method according to any one of claims 416-441, wherein in step ii) one or more pools comprises one or more antigenic peptides P selected from the group consisting of
i) YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), and YIKDINEFI (SEQ ID NO: 4479),
ii) IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112), and/or
iii) IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 443 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442)

The method according to any one of claims 416-442, wherein in step ii) one or more pools comprises one or more antigenic peptides P selected from the group consisting of YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), YIKDINEF (SEQ ID NO: 4479), IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112), IQIEIEQLTDEI (SEQ ID NO: 5126), MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 444 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443)

The method according to any one of claims 416-443, wherein step ii) comprises 3 or more pools of antigenic peptides P wherein
i) Pool 1 comprises YLNTKSNGNYEI (SEQ ID NO: 359), FLSIFTQGYT (SEQ ID NO: 241), GIYDLILNA (SEQ ID NO: 2761), and YIKDINEFI (SEQ ID NO: 4479),
ii) Pool 2 comprises IQIEIEQLTDEI (SEQ ID NO: 5126), RMISDQRANLGA (SEQ ID NO: 5127) and SQGGVNSPV (SEQ ID NO: 5112), and
iii) Pool 3 comprises MLDEAKDKL (SEQ ID NO: 5516), FMEQATNSWI (SEQ ID NO: 5530), NLVFSSLFL (SEQ ID NO: 5510) and KLAESIYKRL (SEQ ID NO: 5531).

### Claim 445 (depends on 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444)

The method according to any one of claims 416-444, further comprising one or more negative control peptides P and/or one or more positive control peptides P.

### Claim 446

The methods according to any one of the preceding claims, wherein the measurement of T cells comprises the step of counting of T cells specific for said MHC multimer.

### Claim 447

The methods according to any one of the preceding claims, wherein the measurement of T cells comprises the step of sorting of T cells specific for said MHC multimer.

### Claim 448

The methods according to any one of the preceding claims, wherein the measurement of T cells comprises the step of isolation of T cells specific for said MHC multimer.

### Claim 449

The methods according to any one of the preceding claims, wherein the number of T cells specific for said MHC multimer is determined from the number of T cells that are bound by more than a given threshold number of MHC multimers.

### Claim 450

The methods according to any one of the preceding claims, wherein the amount of MHC multimers bound to an individual T cell is measured by flow cytometry.

### Claim 451

The methods according to any one of the preceding claims, where the amount of MHC multimers bound to an individual T cell is measured by microscopy.

### Claim 452

The methods according to any one of the preceding claims, wherein the amount of MHC multimers bound to an individual T cell is measured by capture on solid support, optionally followed by elution of T cells.

### Claim 453

The methods according to any one of the preceding claims, wherein the amount of MHC multimers bound to a population of T cells is determined by the total number of MHC multimers bound to the population of T cells.

### Claim 454

The methods according to any one of the preceding claims, wherein the T cells are immobilized.

### Claim 455

The methods according to any one of the preceding claims wherein the MHC multimers are labelled, and the number of individual T cells specific for said MHC multimer is determined using microscopy.

### Claim 456

The methods according to any one of the preceding claims, wherein the MHC multimers are labelled, and the number of T cells specific for said MHC multimer is determined from the total signal of the population of T cells

### Claim 457

The methods according to any one of the preceding claims, wherein the immobilized T cells are part of a solid tissue

### Claim 458

The methods according to any one of the preceding claims, wherein the solid tissue is part of a living animal and the detection of T cells specific for the MHC multimer is performed in vivo.

### Claim 459

The methods according to any one of the preceding claims, wherein the detection of T cells involves magnetic resonance imaging or electron spin resonance scanning.

### Claim 460

The methods according to any one of the preceding claims, wherein the presence, frequency, number, activity and/or state of the T cells specific for said MHC multimer are determined from the result of the interaction of said MHC multimer with said T cells.

### Claim 461

The methods according to any one of the preceding claims, wherein the result of the interaction of said MHC monomer with said T cells is an up- or down-regulation, such as an increased or decreased production, of the amount of a specific factor.

### Claim 462

The methods according to any one of the preceding claims, wherein the specific factor is a secreted soluble factor, an intracellular factor, a mRNA, a cytokine, a surface receptor of T cells, a secreted soluble factor that is captured on solid support, or interferon-gamma (INF-gamma).

### Claim 463

The methods according to any one of the preceding claims, wherein individual T cells are measured.

### Claim 464

The methods according to any one of the preceding claims, wherein populations of T cells are measured.

### Claim 465

The methods according to any one of the preceding claims, wherein the specific factor is immobilized on solid support before measurement of its amount.

### Claim 466

The methods according to any one of the preceding claims, wherein the specific factor is in solution when its amount is measured.

### Claim 467

The methods according to any one of the preceding claims, wherein the result of the interaction of said MHC multimer with the T cell is T cell apoptosis, T cell differentiation or T cell inactivation.

### Claim 468

The methods according to any one of the preceding claims, wherein the measurement of T cells specific for said MHC multimer with the T cell involves flow cytometry.

### Claim 469

The methods according to any one of the preceding claims, wherein the measurement of antigen-specific T cells comprises flow cytometry.

### Claim 470

The methods according to any one of the preceding claims, wherein the measurement of antigen-specific T cells comprises indirect measurement of individual T cells or of populations of T cells.

### Claim 471

The methods according to any one of the preceding claims, wherein the measurement of antigen-specific T cells involves immunohistochemistry (IHC).

### Claim 472

The methods according to any one of the preceding claims, wherein the measurement of antigen-specific T cells involves limited dilution assay (LDA).

### Claim 473

The methods according to any one of the preceding claims, wherein the measurement of antigen-specific T cells involves microscopy.

### Claim 474

The methods according to any one of the preceding claims, wherein the method comprises the step of detecting one or more marker molecules associated with the MHC multimer.

### Claim 475

The methods according to any one of the preceding claims, wherein the one or more marker molecules comprises one or more antibodies and/or antibody fragments, one or more aptamers, one or more proteins, one or more peptides, one or more small organic molecules, one or more natural compounds such as one or more steroids, or one or more non-peptide polymers.

### Claim 476

The methods according to any one of the preceding claims, wherein the method comprises the step of detecting one or more labelling molecules associated with the MHC multimer.

### Claim 477

The methods according to any one of the preceding claims, wherein the one or more labelling molecules comprises one or more labelling molecules that results in directly detectable T cells.

### Claim 478

The methods according to any one of the preceding claims, wherein the one or more labelling molecules comprises one or more labelling molecules that results in indirectly detectable T cells.

### Claim 479

The methods according to any one of the preceding claims, wherein the one or more labelling molecules comprises one or more fluorescent labels, one or more enzyme labels, one or more radioisotopes, one or more chemiluminescent labels, one or more luminescent labels, one or more polymers, one or more metal particles, one or more haptens, one or more antibodies, or one or more dyes.

### Claim 480

The methods according to any one of the preceding claims, wherein the method comprises a detection step based on flow cytometry or flow cytometry-like analysis.

### Claim 481 (depends on 1095)

The methods according to any one of the preceding claim 1095, wherein the method comprises direct detection of TCRs attached to a lipid bilayer.

### Claim 482

The methods according to any one of the preceding claims, wherein the method comprises direct detection of one or more individual T cells in a fluid sample.

### Claim 483

The methods according to any one of the preceding claims, wherein the method comprises direct detection of one or more populations of T cells in a fluid sample.

### Claim 484

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual T cells in a fluid sample comprises flow cytometry.

### Claim 485

The methods according to any one of the preceding claims, wherein the direct detection of one or more populations of T cells in a fluid sample comprises flow cytometry.

### Claim 486

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual T cells in a fluid sample comprises microscopy.

### Claim 487

The methods according to any one of the preceding claims, wherein the direct detection of one or more populations of T cells in a fluid sample comprises microscopy.

### Claim 488

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual T cells in a fluid sample comprises capture of T cells on a solid support followed by elution of said T cells.

### Claim 489

The methods according to any one of the preceding claims, wherein in the direct detection of one or more populations of T cells in a fluid sample comprises capture of T cells on a solid support followed by elution of said T cells.

### Claim 490

The methods according to any one of the preceding claims, wherein the method comprises direct detection of one or more individual immobilized T cells.

### Claim 491

The methods according to any one of the preceding claims, wherein the method comprises direct detection of one or more populations of immobilized T cells.

### Claim 492

The methods according to any one of the preceding claims, wherein one or more individual T cells, or one or more populations of T cells, are immobilized on a solid support such as particles, beads, biodegradable particles, sheets, gels, filters, membranes, nylon membranes, fibres, capillaries, needles, microtitre strips, tubes, plates, wells, combs, pipette tips, micro arrays, chips and slides.

### Claim 493

The methods according to any one of the preceding claims, wherein the immobilization of one or more individual T cells, or one or more populations of T cells, are directly immobilized on the solid support; optionally immobilized through a linker on the solid support.

### Claim 494

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual immobilized T cells, or one or more populations of immobilized T cells, comprises phenotyping a T cell sample using MHC multimer beads.

### Claim 495

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual immobilized T cells, or one or more populations of immobilized T cells, comprises detection of T cells immobilized to solid support in a defined pattern.

### Claim 496

The methods according to any one of the preceding claims, wherein the direct detection of one or more individual immobilized T cells, or one or more populations of immobilized T cells, is followed by sorting of said T cells.

### Claim 497

The methods according to any one of the preceding claims, wherein the method comprises direct detection of one or more individual T cells, or one or more populations of T cells, in a solid tissue either in vitro or in vivo.

### Claim 498

The methods according to any one of the preceding claims, wherein the method comprises indirect detection of one or more populations of T cells in a sample, or one or more individual T cells in a sample.

### Claim 499

The methods according to any one of the preceding claims, wherein the method comprises indirect detection of one or more individual T cells, one or more populations of T cells, in a sample by measurement of activation.

### Claim 500

The methods according to any one of the preceding claims, wherein the indirect detection of one or more individual T cells, or one or more populations of T cells, in a sample comprises measurement of secretion of soluble factors, such as measurement of extracellular secreted soluble factors or such as measurement of intracellular secreted soluble factors

### Claim 501

The methods according to any one of the preceding claims, wherein the measurement of extracellular secreted soluble factors comprises analysis of a fluid sample; detection of T cells by capture of extracellular secreted soluble factor on a solid support; detection of T cells immobilized to solid support in a defined pattern; or detection of T cells by measurement of effect of extracellular secreted soluble factor.

### Claim 502

The methods according to any one of the preceding claims, wherein the indirect detection of individual or populations of T cells in a sample comprises measurement of expression of one or more receptors.

### Claim 503

The methods according to any one of the preceding claims, wherein the indirect detection of individual or populations of T cells in a sample comprises measurement of T cell effector function.

### Claim 504

The methods according to any one of the preceding claims, wherein the method comprises indirect detection of individual or populations of T cells in a sample by measurement of T cell proliferation.

### Claim 505 (depends on 1095)

The methods according to any one of the preceding claim 1095, wherein the method comprises indirect detection of individual or populations of T cells in a sample by measurement of T cell inactivation such as measurement of blockage of TCR and/or measurement of induction of apoptosis.

### Claim 506

The methods according to any one of the preceding claims, wherein the method comprises immunohistochemistry or immunohistochemistry-like analysis.

### Claim 507

The methods according to any one of the preceding claims, wherein the method comprises a measuring step involving an ELISA or ELISA-like analysis.

### Claim 508

The methods according to any one of the preceding claims, wherein the antigen-specific T cells are isolated using MHC multimers immobilized on a solid phase.

### Claim 509

The methods according to any one of the preceding claims, wherein the solid phase is selected from the group consisting of a bead, immunotubes, microtiter plates, microchips, microarrays and test strips.

### Claim 510

The methods according to any one of the preceding claims, wherein the method comprises blocking of the sample and/or of the MHC multimer with a protein solution such as BSA or skim milk.

### Claim 511

The methods according to any one of the preceding claims, wherein the method comprises mixing of MHC multimer coated beads with the cell sample and/or incubation of MHC multimer coated beads with the cell sample.

### Claim 512

The methods according to any one of the preceding claims, wherein the method comprises a washing step after incubation of MHC multimer coated beads with the cell sample.

### Claim 513

The methods according to any one of the preceding claims, wherein the method comprises release of the immobilized T cells from the beads.

### Claim 514

The methods according to any one of the preceding claims, wherein the T cells are released by cleavage of the linker, by changing the pH, by changing the salt concentration, by addition of one or more competitive binders and/or by a method that does not disrupts the integrity of the cells.

### Claim 515

The methods according to any one of the preceding claims, wherein the method comprises manipulation of the T cells after release from the beads.

### Claim 516

The methods according to any one of the preceding claims, wherein the method comprises manipulation of the T cells after release from the beads, wherein the manipulation is induction of apoptosis, induction of proliferation or induction of differentiation.

### Claim 517

The methods according to any one of the preceding claims, wherein the sample to be analysed is acquired from the bone marrow, the blood, the lymph, a solid tissue sample or a suspension of a tissue sample.

### Claim 518

The methods according to any one of the preceding claims, wherein the sample to be analysed is acquired from solid tissue, solid tissue section or a fluid such as whole blood, serum, plasma, nasal secretions, sputum, urine, sweat, saliva, transdermal exudates, pharyngeal exudates, bronchoalveolar lavage, tracheal aspirations, cerebrospinal fluid, synovial fluid, fluid from joints, vitreous fluid, vaginal or urethral secretions, or disaggregated cellular tissues such as hair, skin, synovial tissue, tissue biopsies and nail scrapings.

### Claim 519

The methods according to any one of the preceding claims wherein the sample to be analysed is acquired from cell suspensions derived from tissue samples or cell lines.
